JASON CHESNEY, M.D., Ph.D.

Kosair Charities Clinical and Translational Research Building, Room 424
University of Louisville Health Sciences Campus
505 South Hancock Street, Louisville, Kentucky 40202
502-852-3679 (tel); 502-852-3661 (fax)
jason.chesney@louisville.edu

A. EDUCATION

1987-1991	**B.A.**	Anthropology, University of Minnesota, Minneapolis, MN (*Mentor: John W. Eaton, Ph.D.*)
1993-1997	**Ph.D.**	Biomedical Sciences, University of Minnesota Graduate School, Minneapolis, MN (*Mentors: Richard Bucala, M.D., Ph.D. and Kathleen Conklin, Ph.D.)*
1991-1998	**M.D.**	University of Minnesota Medical School, Minneapolis, MN (*Mentor: Harry Jacob, M.D.)*

B. ACADEMIC APPOINTMENTS:

1998-2001	**Intern and Assistant Physician**, New York-Presbyterian Hospital, Cornell University, NYC, New York (*Program Director: Mark Pecker, M.D.*)
1998-2001	**Resident**, Memorial Sloan Kettering Cancer Center, NYC, New York (*Program Director: Mark Pecker, M.D.*)
2000-2001	**Senior Scientist**, The Picower Institute for Medical Research, Manhasset, New York (*Mentor: Richard Bucala, M.D., Ph.D.*)
2001-2002	**Clinical Fellow**, Division of Immunology, Weill Medical College, Cornell University, NYC, New York (*Mentor: Kendall Smith, M.D.*)
2003-2005	**Post-Graduate Clinical Training**, Medical Oncology and Hematology, J. G. Brown Cancer Center, University of Louisville, KY (*Mentor: Donald Miller, M.D., Ph.D.*)
2003-2008	**Assistant Professor of Medicine (Research Tenure-Track)**, Division of Hematology/Oncology, Department of Medicine, University of Louisville, KY
2003-2008	**Assistant Professor of Biochemistry and Molecular Biology (Joint Appointment)**, University of Louisville, KY
2003-2008	**Assistant Professor of Pharmacology and Toxicology (Joint Appointment)**, University of Louisville, KY
2005-2012	**Associate Director for Translational Research**, J. G. Brown Cancer Center, University of Louisville, KY
2006-*present*	**Director**, Clinical Research Program, J. G. Brown Cancer Center, University of Louisville, KY
2008-2014	**Associate Professor of Medicine (Tenured)**, Division of Hematology/Oncology, Department of Medicine, University of Louisville, KY
2008-2014	**Associate Professor of Biochemistry and Molecular Biology (Joint Appointment)**, University of Louisville, KY
2008-2014	**Associate Professor of Pharmacology and Toxicology (Joint Appointment)**, University of Louisville, KY
2012-*present*	**Director,** James Graham Brown Cancer Center Biorepository
2012-*present*	**Deputy Director**, James Graham Brown Cancer Center, University of Louisville, KY
2014-*present*	**Professor of Medicine (Tenured)**, Division of Hematology/Oncology, Department of Medicine, University of Louisville, KY
2014-*present*	**Professor of Biochemistry and Molecular Biology (Associate Appointment)**, University of Louisville, KY
2014-*present*	**Professor of Pharmacology and Toxicology (Associate Appointment)**, University of Louisville, KY
2015-*present*	**Brinkley Endowed Chair in Lung Cancer Research**, University of Louisville, KY

C. OTHER POSITIONS

None

D. BOARD CERTIFICATION AND LICENSURE

1999 New York State Medical Licensure (#215025)
2001-2011 Certified, American Board of Internal Medicine
2003 Kentucky State Medical Licensure (#37726)

E. PROFESSIONAL MEMBERSHIPS AND ACTIVITIES

2001 **Member**, Advisory Committee, 1st Intl. Conf. on Tumor Cell Metabolism
2003 **Member***,* Center for Molecular Medicine and Genetics, U. of Louisville
2003 **Co-Organizer***,* 2nd International Conference on Tumor Cell Metabolism
2005 **Co-Organizer***,* 3rd International Conference on Tumor Metabolism
2005 **Reviewer***,* Department of Defense Breast Cancer Research Program
2005 **Reviewer***,* Medical Research Council (United Kingdom)
2006 **Chair***,* 4th International Conference on Tumor Metabolism
2006 **Judge***,* Southern Society for Clinical Investigation Oncology Forum
2007 **Chair**, Cell Biology Peer Review Committee, Department of Defense Congressionally Directed Breast Cancer Research Program
2007 **Judge***,* Southern Society for Clinical Investigation Oncology Forum
2007 **Reviewer and Substitute Chairperson***,* Immunological Sciences Committee DOD Congressionally Directed Prostate Cancer Program
2008 **Chair**, Immunological Sciences Committee (Special Session) DOD Congressionally Directed Prostate Cancer Research Program
2008 **Reviewer***,* Immunological Sciences Committee DOD Congressionally Directed Breast Cancer Research Program
2009 **Moderator***,* Hematology/Oncology II, Southern Society for Clinical Investigation
2009 **Reviewer**, RC1 NIH Challenge Grants in Health and Science Research
2009 **Organizer and Chair**, 5th International Conference on Tumor Cell Metabolism
2010 **Chair**, Immunology II Study Section, DOD Congressionally Directed Breast Cancer Research Program
2010 **Member**, Southern Society of Clinical Investigation
2010 **Reviewer,** Immunological Sciences Committee DOD Congressionally Directed Prostate Cancer Research Program
2010 **Reviewer,** Immunological Sciences Committee DOD Congressionally Directed Breast Cancer Research Program
2010 **Panelist**, Novartis LEAD Summit In Oncology
2010 **Chair**, Endocrinology and Immunology DOD Congressionally Directed Breast Cancer Research Program
2010 **Reviewer,** National Cancer Institute Study Section, SPORE (Specialized Programs of Research Excellence) in Lung, Sarcoma, Brain, Melanoma, Prostate and Liver, Washington DC
2011 **Reviewer,** National Cancer Institute Study Section, Tumor Cell Biology, Washington, D.C.
2011 **Reviewer,** National Cancer Institute Study Section, SPORE (Specialized Programs of Research Excellence) in Lung, Sarcoma, Brain, Melanoma, Prostate and Liver, Washington DC
2012 **Reviewer,** National Cancer Institute Study Section, SPORE (Specialized Programs of Research Excellence) in Lung, Sarcoma, Brain, Melanoma, Prostate and Liver, Washington DC
2012 **Member**, E7272-701 Interim Review Committee of Phase II Trial of Denileukin Diftitox

Efficacy in Melanoma

2012 **Organizer**, Clinical Investigator Training Program, University of Louisville (Sponsored by Pfizer and the JG Brown Cancer Center)

2012 **Reviewer**, Wiltshire, United Kingdom Biotechnology and Biological Science Research Council

2012 **Chair,** Regulation of Metabolism in Cancer Meeting, Cold Spring Harbor Laboratory, New York (Co-Chairman, James D. Watson)

2012 **Reviewer,** National Cancer Institute Study Section, Tumor Cell Biology, Washington, D.C.

2012 **Reviewer**, National Cancer Institute Study Section, Cancer Etiology; ZRG1 OBT M 02 R, Teleconference

2013 **Reviewer**, National Cancer Institute Study Section, Ruth L. Kirschstein NRSA Individual Fellowship Mechanism (Winter Session)

2013 **Reviewer**, National Cancer Institute Study Section, Ruth L. Kirschstein NRSA Individual Fellowship Mechanism (Summer Session)

2013 **Reviewer***,* Immunological Sciences Committee DOD Congressionally Directed Breast Cancer Research Program, Washington DC

2013 **Reviewer,** National Cancer Institute Study Section, SPORE (Specialized Programs of Research Excellence) in Lung, Sarcoma, Brain, Melanoma, Prostate and Liver, Washington DC

2013 **Reviewer,** National Cancer Institute Study Section, Tumor Cell Biology, San Francisco

2013 **Chair**, Ovarian Cancer Research Program Study Section, Research Development Awards, DOD Congressionally Directed Breast Cancer Research Program, Washington D.C.

2013 **Chair**, Tumor Immunology Study Section, Breakthrough Awards, DOD Congressionally Directed Breast Cancer Research Program, Washington D.C.

2014 **Reviewer,** National Cancer Institute Study Section, Provocative Questions Initiative, Washington D.C.

2014 **Co-Chair** and **Reviewer,** National Cancer Institute Study Section, SPORE (Specialized Programs of Research Excellence) in Lung, Sarcoma, Brain, Melanoma, Prostate and Liver, Washington D.C.

2014-*present* **Full Member**, **American Association for Cancer Research**

2014 **Chair,** Clinical and Experimental Therapeutics Study Section, Congressionally-Directed Medical Research Program (Breast Cancer), Washington D.C.

2014 **Reviewer,** National Cancer Institute Study Section, Tumor Cell Biology, Teleconference

2014 **Chair,** Cell Biology Peer Review Panel, Congressionally-Directed Medical Research Program (Ovarian Cancer Research Program), Teleconference

2014 **Discussion Leader** and **Reviewer,** National Cancer Institute Study Section, SPORE (Specialized Programs of Research Excellence) in Lung, Sarcoma, Brain, Melanoma, Prostate and Liver, Washington D.C.

2015 **On-Site Reviewer**, P30 National Cancer Institute-Designated Cancer Center Study Section, Albuquerque, New Mexico

2015 **Discussion Leader** and **Reviewer,** National Cancer Institute Study Section, SPORE (Specialized Programs of Research Excellence) in Lung, Sarcoma, Brain, Melanoma, Prostate and Liver, Washington D.C.

2015-*present* **Full Member**, **American Society of Clinical Oncology**

2015 **Organizer and Chair**, Twisted Pink Scientific Conference of Metastatic Breast Cancer, Louisville, KY

2015-2019 **Standing Member**, National Cancer Institute's Tumor Cell Biology Study Section

F. HONORS AND AWARDS

1990 **Undergraduate Research Award**, University of Minnesota

1991 ***Summa cum laude***, Anthropology, University of Minnesota

1991 **Phi Kappa Phi**
1991-1998 **Medical Scientist Training Program Scholarship**, N.I.H.
1993 **Phi Beta Kappa**
1997 **Livermore Award in Hematology**, Minnesota Medical Foundation
2005 **Young Faculty Award**, American Federation for Medical Research
2009 **Bedside-to-Bench Manuscript Award in Translational Research** (*Corresponding Author*, Journal of Translational Medicine)
2011 **Scientist of the Year Award,** Julep Ball, Brown Cancer Center, U. of Louisville
2011, 2012 **US News & World Report Top Doctor** (Melanoma-Advanced, Solid Tumors and Clinical Trials)
2015 **Brinkley Endowed Chair in Lung Cancer Research**, University of Louisville

G. COMMITTEE ASSIGNMENTS AND ADMINISTRATIVE SERVICES

University of Louisville

2003-2013 **Member***,* Institutional Biosafety Committee (IBC), University of Louisville
2004-2006 **Member***,* Institutional Animal Care and Use Committee (IACUC), University of Louisville
2004-2006 **Member***,* Promotions and Tenure Committee, Department of Medicine
2004-2006 **Member***,* Biomedical III/IV Research Laboratory Design Committee
2006-2009 **Reviewer**, University of Louisville CEGIB Pilot Grant Review Committee
2012-2013 **Vice Chair,** Search Committee, Chair of the Department of Microbiology and Immunology, University of Louisville
2003-*present* **Member***,* MD-PhD Program Steering Committee, University of Louisville
2009-2014 **Co-Chair**, Promotion, Appointment and Tenure Committee, Department of Medicine, School of Medicine, University of Louisville
2013-2014 **Member,** University of Louisville School of Medicine Strategic Planning Committee for Research
2013-2014 **Member,** Search Committee: Director of the Human Subjects Protection Committee, University of Louisville
2013-2014 **Chairperson,** Search Committee: Chief, Division of Pulmonary, Critical Care, and Sleep Disorders Medicine, Department of Medicine
2013-*present* **Member,** University of Louisville Faculty Research Advisory Council
2014-*present* **Member,** School of Medicine Strategic Planning Steering and Working Committee

James Graham Brown Cancer Center

2007-2009 **Member***,* Internal Advisory Committee, Kosair Children's Cancer Research Program
2005-*present* **Member**, Clinical and Scientific Review Committee, James Graham Brown Cancer Center
2006-*present* **Member***,* COBRE in Molecular Targets Executive Committee
2006-*present* **Chair***,* Data Safety Monitoring Committee, James Graham Brown Cancer Center
2006-*present* **Co-Leader**, Molecular Targets Program, James Graham Brown Cancer Center
2006-*present* **Member**, Clinical Trials Oversight Committee, James Graham Brown Cancer Center
2011-*present* **Chair,** Specimen Utilization Committee, James Graham Brown Cancer Center
2012-*present* **Director**, Hem/Onc-PhD Program, James Graham Brown Cancer Center
2013-*present* **Chair,** Search Committee, Director of Cancer Control Program, James Graham Brown Cancer Center
2013-*present* **Chair,** James Graham Brown Cancer Center New Investigator R01 and R21 Study Section
2014-*present* **Member,** Search Committee, Structural Biology Translational Research Faculty
2014-*present* **Presenter and Guide,** The Brown Cancer Center and CTRB Fundraising Tour

H. JOURNAL PEER REVIEWS

Ad Hoc Reviewer (year listed for first review)

1995-2001 Molecular Medicine
2006-*present* Cancer Research
2008-*present* Nature Medicine
2008-*present* Cancer Chemotherapy and Pharmacology
2009-*present* Molecular Cancer Research
2009-*present* PNAS
2009-*present* Molecular Cancer Therapeutics
2010-*present* Current Pharmaceutical Biotechnology
2010-*present* Journal of Biological Chemistry
2010-*present* Biochemical Journal
2010-*present* Cancer Immunology and Immunotherapy
2011-*present* Journal of Molecular Medicine
2011-*present* Breast Cancer Research
2011-*present* Oncogene
2011-*present* Clinical & Experimental Metastasis
2012-*present* Drugs (ADIS)
2012-*present* Molecular Cancer
2012-*present* PLOS One
2012-*present* BBA Molecular Cell Research
2012-*present* Cancer and Metabolism
2012-*present* BMC Cancer
2012-*present* Journal of Clinical Investigation
2013-*present* Cell Death and Differentiation (Nature)
2013-*present* Critical Reviews in Biochemistry and Molecular Biology
2014-*present* Oncotargets
2015-*present* Cancer Cell

I. BOARD PARTICIPATION

2011 **Member,** Oncovex Advisory Board, Biovex, Dallas TX
2012, 13, 14 **Member,** Scientific Advisory Board for Talimogene Laherparepvec, Amgen, Dallas TX
2013 **Member,** Global Oncology Advisory Board, Amgen, Thousand Oaks CA
2014-*present* **Member,** Scientific Advisory Board, Louisville Bioscience Inc., Louisville KY
2014 **Member**, Clinical Advisory Board for Nivolumab (Anti-PD1), Bristol Myers Squibb, NYC
2014 **Member**, Bristol Myers Squib Scientific Advisory Board, Immune Checkpoint Inhibitors
2014-*present* **Member**, Commonwealth of Kentucky Lung Cancer Research Governance Board
2015 **Member**, Advanced Melanoma Advisory Board, Bristol Myers Squib, Orlando FL
2015 **Member**, T-VEC Combination Studies Global Advisory Board, Amgen, Houston TX

J. TEACHING

Course Teaching

2005-2009 **Course Master**, Hematology/Oncology Fellowship Translational and Clinical Research Course
2006-2012 **Lecturer**, Biology of Cancer graduate school course (Bioc675) (2 courses: Tumor Metabolism and Current Chemotherapeutic Strategies in Cancer)
2006-2013 **Lecturer**, Biochemistry 547/647, Tumor Cell Metabolism
2007-*present* **Lecturer**, Hematology/Oncology Fellowship Program Core Curriculum, Melanoma

2009-2011 **Lecturer**, Internal Medicine Residency Program Didactics, Melanoma

2009-*present* **Lecturer**, U. of Louisville Medical School Pharmacology Course: Clinical Correlations in Chemotherapy

2013-*present* **Co-Director**, Essentials of Translational Cancer Biology (under development - to initiate in 2016 in the Translational Cancer Biology Program, School of Interdisciplinary Graduate Studies)

2013-*present* **Co-Director**, Clinical Cancer Biology Internship (under development - to initiate in 2016 in the Translational Cancer Biology Program, School of Interdisciplinary Graduate Studies)

2014 **Lecturer**, U. of Louisville School of Medicine, First Year Class, Interactive Case Presentation and Learning

Research/Laboratory Teaching

Undergraduates

1994-1995 June Han, Brown University, The Picower Institute

2003-2004 Jonathan Sims, Western Kentucky University

2005 Hugh Evans, University of Louisville

2013-*present* Conor O'Neill, University of Kentucky

2015-*present* Andrew Bratton, University of Louisville

Masters Students

2003-2004 Natalie Wallis, B.A., University of Louisville

Graduate Students

2003-2008 Abdullah Yalcin, D.V.M., University of Louisville

2003-2008 Joshua Thornburg, University of Louisville

2015-*present* Jaspreet Grewal, M.D., Hem/Onc-PhD Program, University of Louisville

2014-*present* Robert Spaulding, MD-PhD Program, University of Louisville

2015-*present* Selahattin Can Ozcan, Visiting Scholar, Uludag University, Turkey

Medical Students

2003-2007 Alan Simmons, Ph.D., University of Louisville

2007 Alden Klarer, University of Louisville

2007-2009 Mary Ann Rasku, University of Louisville

2010 Neil Crittendon, University of Louisville

2010 Jessica N Mezzanotte (MD-PhD), University of Louisville

2010-2011 Whitney Goldsberry (MD-PhD), University of Louisville

2012-2014 Robert Spaulding (MD-PhD), University of Louisville

2013 Mariam Hannah, University of Louisville

2014 Jordon Noe (MD-PhD), University of Louisville

2014-*present* Govind Warrier, University of Louisville

Post-Doctoral Fellows

2004-2009 Kristin Nelson, Ph.D., University of Louisville

2005-2009 Brian Clem, Ph.D. University of Louisville

2007-2008 Lili Qi, M.D. University of Louisville

2007-2008 Umesh Goswami, M.B.B.S. University of Louisville

2010-2011 Qiaohong Liu, Ph.D., University of Louisville
2010-2014 Julie O'Neal, Ph.D., University of Louisville
2010-*present* Yoannis Imbert-Fernandez, Ph.D., University of Louisville
2014-*present* Nadijka Lypova, Ph.D., University of Louisville

Internal Medicine Residents
2011-2014 Alan Kerr, Ph.D., University of Louisville

Hematology/Oncology Fellows
2003-2006 Steven Makoni, M.D. University of Louisville
2011-2012 Najendra Natarajan, M.B.B.S. University of Louisville
2012-2014 Ajoy Dias, M.B.B.S., University of Louisville
2015-*present* Tezo Karaden, M.B.B.S., University of Louisville

Surgery Residents
2015 Alison Burton, M.D., University of Louisville

Radiation Oncology Residents
2005-2006 Jessica Guarnaschelli, M.D., University of Louisville

Assistant Professors
2002-2008 Sucheta Telang, M.B.B.S. University of Louisville
2009-2013 Brian Clem, Ph.D., University of Louisville
2013-*present* Nichola Garbett, Ph.D., University of Louisville
2014-*present* Kavitha Yaddanapudi, Ph.D., University of Louisville
2014-*present* Joshua Hood, M.D., Ph.D., University of Louisville

Thesis Committees

Department of Pharmacology/Toxicology

2004-2007	Ph.D.	Chad Dumstorf
2004-2007	Ph.D.	Nicholas Watson
2004-2008	Ph.D.	Joshua Thornburg
2006-2008	Ph.D.	Katharine Richardson
2006	M.S.	Lindsey Jay Stallons
2008	M.S.	Nason Schooler
2009	M.S.	Shyam Suncer Bansal
2006-2009	Ph.D.	LaSharon Mosley
2007-2011	Ph.D.	Lindsey Jay Stallons
2010-2012	Ph.D.	Shyam Suncer Bansal
2013-*present*	Ph.D.	Chris Shidal

Department of Biochemistry and Molecular Biology

2003-2008	Ph.D.	Abdullah Yalcin
2012-*present*	Ph.D.	Robert Spaulding (MD-PhD), University of Louisville

Department of Anatomical Sciences and Neurobiology

2008-2010	M.D./Ph.D.	Janelle Fassbender

Department of Bioinformatics and Biostatistics

2007-2010	Ph.D.	Chris Barnes

Department of Physiology and Biophysics

2010-2012	Ph.D.	Miranda Fong

Department of Microbiology and Immunology

2010-2013	M.D./Ph.D.	Courtney George
2011-2013	Ph.D.	Carolyn Roberson
2013-*present*	Ph.D.	Jaspreet Grewal

Department of Chemistry

2011-2013	M.D./Ph.D.	Alex Belshoff

K. ABSTRACTS AND PRESENTATIONS (2003-*present*)

Invited Extramural Oral Presentations:

07/16/04 **Academic Medicine for MD PhDs: It's all about the start-up package**, MD PhD Program, University of Minnesota, Minneapolis, MN.

02/25/05 **Pharmacophore Targeting of the Fructose-6-Phosphate Binding Site of iPFK-2**, American Federation for Clinical Research, Southern Society for Clinical Investigation Annual Meeting, New Orleans, LA.

01/17/06 **Targeting 6-Phosphofructo-2-Kinase in Cancer**, University of Minnesota Comprehensive Cancer Center External Seminar Series, Minneapolis, MN.

04/11/06 **6-Phosphofructo-2-Kinase: A New Molecular Target for the Development of Cancer Therapeutics**, Sylvester Comprehensive Cancer Center Invited Speaker Seminar Seriers, Miami, Florida.

05/20/06 **Targeting 6-Phosphofructo-2-Kinase In Cancer**. Risk Appraisers Forum (Life Insurance). Galt House, Louisville, KY.

06/01/06 **Molecular Targeting of Cancer: The Battle Is On**. State of the Art Speaker: Oncology. American College of Veterinary Internal Medicine, Louisville KY Convention Center.

06/01/06 **Targeting of the Glycolytic Regulator Inducible 6-Phosphofructo-2-Kinase In Cancer**. State of the Art Speaker: Oncology. American College of Veterinary Internal Medicine, Louisville KY Convention Center.

07/23/06 **Development of Small Molecule Inhibitors of 6-Phosphofructo-2-Kinase as Anti-Neoplastic Agents**. National Center Research Resources IDEA Symposium, Washington D.C.

10/13/06 **Finding Answers to Cancer: Targeted Drugs, Starving Cancer Cells and Cancer Vaccines**. Idea Festival, Louisville, KY.

11/06/06 **Targeting Treg Cells In Melanoma**. Proffered Oral Presentation, Joint EORTC/AACR Molecular Targets Meeting, Prague, The Czech Republic.

06/13/07 **Targeting 6-Phosphofructo-2-Kinase In Leukemia**. Keynote Speaker, Leukemia and Lymphoma Society Gala, Louisville, KY.

10/06/07 **T Cell Depletion In Melanoma**. Keynote Speaker, Browning Melanoma Foundation, Louisville, KY.

10/13/07 **Targeting 6-Phosphofructo-2-Kinase In Leukemia**. Translational Research Program, The Leukemia and Lymphoma Society, New York, NY.

07/02/08 **Discovery to Delivery**. Panelist, Friends of Cancer Research Forum with Deputy Director NCI and FDA Commissioner, Louisville, KY.

09/16/08 **Targeting Regulatory T Cells In Melanoma**. Eisai Global Summit On Ontak, Newark, N.J.

11/10/08 **Strategies to Overcome Regulatory T-Cell Effects in Cancer**. Invited Speaker, Clinical Roundtable Monograph on Emerging Strategies in Regulatory T-Cell Immunotherapy, Clinical Advances in Hematology & Oncology Continuing Medical Education, via Teleconference.

03/05/09 **Transient Treg Depletion Causes Regression of Metastases in Stage IV Melanoma Patients**. Proffered Oral Presentation. Keystone Conference on Regulatory T cells, Keystone, Colorado.

10/02/09 **Cytochrome C Oxidase Is Required for Malignant Transformation**. Invited Oral Presentation. Mitochondria, Apoptosis and Cancer (EMBO) Conference, Prague, Czech Republic.

03/15/10 **Coupling Metabolism with Proliferation** Invited Oral Presentation. Keystone Symposia Conference: Metabolism and Cancer Progression, Vancouver, British Columbia.

03/27/10 **Targeting Glucose Metabolism for Cancer Therapeutics** Invited Oral Presentation. University of Kentucky Joint Lung Cancer Conference, Lexington, KY.

11/01/10 **Coupling Metabolism with Proliferation** Cold Spring Harbor Laboratory's Banbury Center; Dr. James Watson. Cold Spring Harbor, New York.

01/06/11 **Coupling Metabolism with Proliferation.** Agios Pharmaceuticals Round Table Seminar Series, Cambridge, MA

03/16/11 **Fructose-2,6-Bisphosphate: Effects on Metabolism and Cell Proliferation.** Washington University in St. Louis, School of Medicine. Optical Imaging Seminar Series, St. Louis, MO

04/04/11 **Characterization of a Novel Small Molecule Antagonist of 6-Phosphofructo-2-Kinase that Suppresses Glucose Metabolism and Tumor Growth.** Invited Oral Presentation (*senior author but presentation given by co-author Gilles Tapolsky*). American Association for Cancer Research, Orlando, FL

05/17/11 **Coupling Metabolism with Proliferation**. Vesalius Research Center (VRC) Flanders Interuniversity Institute for Biotechnology (VIB) University of Leuven, Campus Gasthuisberg, Leuven, Belgium

06/04/11 **Denileukin Diftitox Increases Serum GM-CSF and Causes Durable Clinical Responses That Are Associated With Prolonged Survival in Stage IV Melanoma.** Proferred Oral Presentation. American Society of Clinical Oncology Annual Meeting, Chicago, IL

05/17/12 **Development of Small Molecule Inhibitors of 6-Phosphofructo-2-Kinases.** Cold Spring Harbor Laboratory, Lloyd Harbor, New York

10/18/12 **Targeting Glycolysis for the Treatment of Cancer**, International Pelvic Society, Louisville, KY

02/08/13 **Targeting a Key Regulator of Glucose Metabolism (PFKFB3) As a Therapeutic Strategy Against Cancer – From Discovery to a Phase I Trial**, University of Florida Shands Cancer Center Topics Lecture, Gainesville, FL

04/09/13 **Ras and Metabolism – From Targets to Trials,** Guest Speaker - Metabolic Changes Associated with Ras-Driven Cancers, Major Symposium at the American Association for Cancer Research Annual Meeting, Washington D. C.

04/06/14 **Identification of a PFKFB3 Inhibitor Suitable for Phase I Trial Testing**, Guest Speaker, "Cancer Metabolism: New Pathways and Progress Toward Therapy Symposium", American Association for Cancer Research Annual Meeting, San Diego, California

04/18/14 **Coupling Cancer Metabolism with Proliferation**, Invited Speaker, Feinstein Institute for Medical Research, Manhasset, New York

05/05/14 **Phase I Trial of a First-In-Class 6-Phosphofructo-2-Kinase Inhibitor,** Invited Speaker, Georgetown University, Phase I Trials Working Group, Georgetown, Maryland

05/28/14 **Fructose-2,6-Bisphosphate Links Glucose to Survival and Growth.** Proferred Oral Presentation, "Metabolism, Diet and Disease: Cancer and Metabolism Conference (BMC)", Georgetown, Maryland

02/09/15 **Targeting PFKFB3 As a Therapeutic Strategy Against Renal Cell Carcinoma,** Invited Speaker, Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD

05/30/15-06/01/15 **A First-In-Class, First-In-Human Inhibitor of PFKFB3 for the Treatment of Cancer**, Presentations to Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi, Astellas, Lilly and Merck Serono, American Society for Clincal Oncology Annual Meeting, Chicago IL

09/18/15 **Clinical response, progression-free survival, and safety in patients with advanced melanoma receiving nivolumab combined with ipilimumab vs ipilimimab monotherapy in the BMS CheckMate 069 study**, 18th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), Xiamen, The Peoples Republic of China (*scheduled*)

Invited Media and Community Presentations

04/01/10 **Role of Clinical Trials in the Management of Cancer,** WAVE3 TV 10AM, Louisville, KY

07/28/10 **Melanoma – Risks, Prevention and Treatment,** WAVE3 TV 10AM, Louisville, KY

04/21/11 **Importance of Julep Ball for the James Graham Brown Cancer Center**, WHAS 9AM Great Day Live, Louisville, KY

07/26/12 **Melanoma – Risks, Prevention, Role of UV Irradiation,** WHAS 9AM Great Day Live, Louisville, KY

05/23/13 **Skin Cancer – Warning Signs and Prevention,** WHAS 9AM Great Day Live, Louisville, KY

06/18/13 **Risks of Tanning Beds**, WHAS 9AM Great Day Live (TV), Louisville, KY

06/18/13 **Special Report on FDA's New Tanning Bed Regulations**, WHAS 5 PM News, Louisville, KY

06/19/13 **Rising Incidence of Melanoma in Young Women**, WLKY TV Interview, Louisville, KY (Aired in November 2013)

07/11/13 **Strides Being Made at the Brown Cancer Center**, Louisville Rotary Club, Louisville, KY

10/25/13 **Disparities in Cancer**, Kentucky African Americans Against Cancer Annual Meeting, Keynote Presentation

12/11/13 **Melanoma and Kentucky**, WAVE-TV, Louisville, KY

06/13/14 **Recruitment to Clinical Trials**, Commonwealth Radio Reports, Richard Farmer

06/13/14 **Patient-Focused Clinical Trials**, "Medical Digest" with Jean West, WAVE3-TV, Lousiville, KY

09/23/14 **Anti-PD1 (Keytrude/Pembrolizumab) for Cancer,** WAVE3 TV and WLKY TV, Louisville KY

11/23/14 **Need for Improved Breast Cancer Diagnostics and Therapeutics in Kentucky,** Horses and Hope Race Day 2014, Churchill Downs, Louisville KY

03/03/15 **Breast Cancer - A Presentation to the Twisted Pink Foundation Board,** Clinical and Translational Research Building, Louisville, KY

04/19/15 **Curing Cancer Through Translational Research**, American Cancer Society Relay for Life, University of Louisville, KY

04/28/15 **Risks of Tanning Beds**, Courier Journal Interview, Published in Sunday Edition Health Section, May 17, 2015

05/18/15 **Protecting Your Children from the Sun and Melanoma**, Interview, WHAS11 TV News, Louisville, Kentucky

06/01/15 **Virus Versus Cancer: Modified Herpes Virus Attacks Melanoma**, Interview, Front Page and Page 3, USA Today

06/04/15 **Louisville Researchers Use Herpes Virus in Clinical Trial to Treat Cancer**, Interview, WFPL News, 89.3 FM

06/05/15 **Groundbreaking Cancer Treatment Saved Ashland Woman's Life,** Interview, Daily Independent Newspaper, Ashland, KY

06/07/15 **Fight Cancer With a Virus**, Interview, Front Page Article, Sunday Courier Journal
06/19/15 **Killing Cancer With Viruses**, Interview, WLKY TV News, Louisville KY
07/15/15 **Immunotherapy: Can we convince our own immune cells to kill off cancer?**, "Beer With a Scientist. Against the Grain Restaurant and Brewery, Louisville, KY
07/30/15 **Cancer Research at the University of Louisville,** Interview (with Paula Bates and Donald Miller), "The Ville", 93.9FM

Invited Intramural Oral Presentations (University of Louisville):

09/05/02 **Fibrocytes**, Poa Pratensis Seminar Series (Molecular Targets, JGBCC).
09/18/02 **Mr. Embden and Mr. Meyeroff Meet the Accelerator**, Keynote Presentation, JG Brown Cancer Center Retreat.
10/16/02 **Becoming a Physician-Scientist**, University of Louisville MD/PhD Program Seminar Series.
10/17/02 **Flipping the Master Switch to OFF *and* Catching Viruses (before they catch you)**, Department of Pharmacology and Toxicology Faculty and Student Seminar Series.
11/21/02 **Spotting New Viruses (Before They Cause Spots)** , Department of Medicine Grand Rounds.
01/17/03 **Tumor Metabolism: Mr. Embden and Mr. Meyerhof Meet the Accelerator**, Biochemistry/Molecular Biology Seminar Series.
05/29/03 **Extraterrestrial DNA,** Poa Pratensis Molecular Targets Seminar Series .
10/09/03 **The Dark Side of iPFK2,** Poa Pratensis Molecular Targets Seminar Series.
10/16/03 **Lucky Strikes as a Hapten,** Poa Pratensis Molecular Targets Seminar Series.
03/31/04 **Universal Virus Detection,** U. of L. Development Office.
11/11/04 **Targeting Ras-Transformed, p53 Mutant Cancer Cells In Situ,** Poa Pratensis Molecular Targets Seminar Series.
07/21/05 **Killing the Gladiators' Guards to Slay the Evil Melanoma,** Poa Pratensis Molecular Targets Seminar Series.
09/19/05 **6-Phosphofructo-2-Kinase (PFKFB3) in Cancer: An Example of Academic Drug Development,** Hematology/Oncology Translational Seminar Series.
01/12/06 **Targeting 6-Phosphofructo-2-Kinase in Cancer**, Poa Pratensis Molecular Targets Seminar Series. Baxter II Building, U. of L.
05/15/06 **Using Anti-Glut1 To Cream Cancer.** Molecular Targets Program Retreat, Brown Hotel, Louisville KY
06/01/06 **Targeting T Regulatory Cells In Human Cancer.** Department of Medicine Grand Rounds.
03/27/07 **Depletion of T Regulatory Cells Causes Tumor-Specific Immunity and Tumor Regressions In Metastatic Melanoma Patients**. Poa Pratensis Molecular Targets Seminar Series. Baxter II Building, U. of L.
06/08/07 **New Therapies for Advanced Melanoma.** U. of L. Dermatology Residency Program
07/17/07 **Targeting Glucose Metabolism or T Cells In Cancer?** U. of Louisville Pharmacology/Toxicology Seminar Series
08/14/07 **Targeting Glucose Metabolism of T Cells In Cancer? A Repeat Performance** U. of Louisville, J.G. Brown Cancer Center Cancer Prevention Program
01/31/08 **Transient T Cell Depletion Causes Regression of Melanoma Metastases (In Humans**) Department of Microbiology and Immunology Seminar Series, U. of Louisville
11/17/08 **Targeting of Metabolic Enzymes and Drug Development** U. of Louisville, J.G. Brown Cancer Center, Hematology/Oncology Fellowship Journal Club
08/11/09 **Overall Survival After Depletion of Regulatory T cells in Stage IV Melanoma** U of Louisville Melanoma Seminar Series (Dept Surgery)
09/18/09 **Tumor Cell Metabolism** President Ramsey's Outreach Program, Shelby High School (Shelbyville) and Western Hills High School (Frankfort)
09/23/09 **Development of PFKFB3 Inhibitors** University of Louisville, for GlaxoSmithKline Cancer Metabolism Group, CTRB

09/23/09 **Development of Choline Kinase Inhibitors** University of Louisville, for GlaxoSmithKline Cancer Metabolism Group, CTRB

11/06/09 **Translating Metabolism Into Cancer Therapeutics**, J. G. Brown Cancer Center Annual Retreat, Olmstead Manor, Louisville, KY

11/21/09 **Targeting Choline Kinase As a Therapeutic Strategy In Cancer,** Joint UofL J.G. Brown Cancer Center and UK Markey Cancer Center Lung Cancer Symposium, CTRB, University of Louisville

12/02/09 **Targeting T(reg) Cells with Recombinant IL-2/Diphtheria Toxin in Stage IV Melanoma Patients**, JG Brown Cancer Center Seminar Series, CTRB

01/28/10 **Tumor Cell Metabolism and Careers in Science and Medicine** President Ramsey's Outreach Program, Trinity High School Senior AP class

04/01/10 **Clinical Trials at the University of Louisville** WAVE3 Listens

04/21/10 **Five Interesting Melanoma Cases From an Immunologist's Perspective** Department of Surgery Melanoma Conference

04/23/10 **Clinical and Translational Research at the Brown Cancer Center** BCC Regional Cancer Committee Board Strategic Planning Retreat

05/20/10 **Coupling Metabolism with Proliferation** The Molecular Targets Program Seminar Series.

06/30/10 **Update on Development of PFKFB3 and Choline Kinase Inhibitors** Advanced Cancer Therapeutics Annual Shareholders Meeting, CTRB, U. of Louisville

07/21/10 **Clinical and Translational Research at the Brown Cancer Center** Introduction to Clinical Research Seminar Series

08/12/10 **Five Interesting Melanoma Cases From an Immunologist's Perspective** Poa Pratensis Molecular Targets Seminar Series

08/18/10 **An Interesting Stage IV Melanoma Case: SM** Department of Surgery Multi-Disciplinary Melanoma Conference

04/08/11 **Interim Analysis of Denileukin Diftitox Phase II Trial In Stage IV Melanoma: Wolchok Criteria and Future Directions.** Roundtable Between Quintiles and the Brown Cancer Center, CTRB, U. of Louisville

04/13/11 **Targeting Glycolytic and Mitochondrial Metabolism.** Metabolism and Cancer Therapeutics Workshop, CTRB, U. of Louisville

04/20/11 **Ipilimumab, Denileukin Diftitox and B-Raf Inhibitors For Stage IV Melanoma.** Department of Surgery Melanoma Conference.

06/06/11 **Novel Immunotherapeutic Agents & Small Molecule Antagonists of Signaling Kinases for the Treatment of Metastatic Melanoma** Department of Medicine Grand Rounds

09/28/11 **Alternative Fuel Phentypes and Lactate Metabolism in NSCLC and HBEC** Metabolism Working Group Meeting, JGBCC, U. of Louisville

09/28/11 **Panel of MD, PhD Physician-Scientists** M.D./Ph.D. Program, CTRB #123, U. of Louisville

10/13/11 **Siddhartha Mukherjee, M.D., Ph.D.: Moderator for UofL Medical Students**, U. of Louisville School of Medicine, Instructional Building, Room 202

10/28/11 **Perturbation of T Cell Control Can Trigger Objective Responses in Cancer Patients,** James Graham Brown Cancer Center Annual Retreat, Olmstead Center

11/16/11 **T Cell Control and Novel Therapeutic Strategies for Melanoma,** Department of Surgery Melanoma Conference, U. of Louisville

12/07/11 **NADH:Ubiquinone Oxidoreductase and Lung Cancer**, Metabolism Working Group Meeting, JGBCC, U. of Louisville

01/05/12 **Extracting the Sweet Tooth Out of T Cells,** Molecular Targets Seminar Series, CTRB, U. of Louisville

01/13/12 **Translational Research at the James Graham Brown Cancer Center**, Distinction in Research Program, U. of Louisville School of Medicine

01/18/12 **Targeting 6-Phosphofructo-2-Kinase in Cancer**, Division of Endocrinology, Metabolism and Diabetes Multidisciplinary Endocrine Conference

03/01/12 **T Cell Control in Cancer Patients,** Division of Dermatology, U. of Louisville School of Medicine

04/06/12 **Targeting the Glycolytic Metabolism of Cancer Cells**, Department of Ophthalmology and Visual Sciences Seminar, U. of Louisville School of Medicine

07/12/12 **Curing Cancer Using Basic Discoveries** University of Louisville PEPP Program for Talented Undergraduate Students, JGBCC, U. of Louisville

07/12/12 **Innovation and Research at UofL – Impact on Regional Economy** Louisville Healthcare Fellows Program, Clinical and Translational Research Building, U. of Louisville

07/16/12 **Basic and Clinical Research Programs at the JGBCC** Regional Cancer Center Corporation, Clinical Translational Research Building, U. of Louisville

07/20/12 **(Some) Key Discoveries in Cancer Drug Development-1876 to Present** Brown Cancer Center Grand Rounds, ACB Auditorium, U. of Louisville

07/26/12 **Risks of Cancer and Aging Related to Sun Exposure** Broadcast on WHAS Great Day Live Laura Rogers, WHAS Studio, Louisville, Kentucky

08/23/12 **Need for Clinical Trials In Oncology** Division of Infusion Nursing, Brown Cancer Center

08/27/12 **Melanoma – The Basics** Medical Oncology/Hematology Fellowship Program Summer Series, James Graham Brown Cancer Center

09/05/12 **Cancer Education, Care, Research and Trials at the Brown Cancer Center** Leukemia and Lymphoma Society Meet the Researcher Seminar, CTRB

10/18/12 **Targeting PFKFB3 in Pediatric Cancers** Pediatric Hematology/Oncology Grand Rounds, U. of Louisville

02/04/13 **Cancer Clinical Trials Program** University of Louisville Hospital Nursing Orientation

02/15/13 **Key Discoveries in Cancer Drug Development – 1800s to Present** U. of Louisville Weekend College, Naples FL

02/26/13 **Targeted and Immunotherapeutic Strategies for Melanoma – Phase I to Phase III Trials** U. of Louisville Dept of Surgery (Surgical Oncology) Seminar

03/18/13 **Update of Translational Research at the Brown Cancer Center** Regional Cancer Center Corporation, Louisville Kentucky

04/04/13 **Ras and Metabolism – From Targets to Trials** Molecular Targets Program Seminar Series, CTRB 123, University of Louisville

04/17/13 **Novel Immunotherapeutic and Targeted Strategies for Melanoma**, Department of Surgery, U. of Louisville

07/24/13 **Conducting Clinical Trials at an Academic Institution**, MD/PhD Program, U. of Louisville

10/25/13 **Development of Metabolic Inhibitors**, J. G. Brown Cancer Center Retreat, U. of Louisville

01/15/14 **Novel Targeted and Immune-Based Therapies for Stage IV Melanoma**, Melanoma Conference, Department of Surgery, U. of Louisville

03/05/14 **Coupling Glucose Metabolism with Cell Cycle Progression**, Cancer Biology and Therapeutics Colloquia, U. of Louisville

03/08/14 **Novel Immunotherapeutic and Targeted Agents for the Treatment of Melanoma**, J. G. Brown Cancer Center Grand Rounds, U. of Louisville

04/03/14 **Development of a First-In-Class 6-Phosphofructo-2-Kinase (PFKFB3) Inhibitor for Phase I Trial Testing in Advanced Cancer Patients** The 2014 Theodore Segal Lecture, UofL Dept of Medicine Grand Rounds

04/22/14 **Curing Cancer**, Omicron Kappa Upsilon (OKU) Society, UofL School of Dentistry, Key Note Speaker, Louisville Boat Club

08/15/14 **Melanoma: At the Forefront of Targeted and Immunotherapeutic Agents for Cancer**, Dept. of Surgery Grand Rounds, U. of Louisville

09/16/14 **Phase I Trial of PFK158 in Advanced Cancer Patients,** Research!Louisville, U. of Louisville

04/01/15 **Targeting Immune Checkpoint Proteins and Cells in Cancer**, Cancer Biology and Therapeutics Seminar Series, U. of Louisville

07/10/15 **Melanoma: At the Forefront of Targeted and Immunotherapeutic Strategies Against Cancer**, Division of Dermatology, Dept. of Medicine, U. of Louisville

07/14/15 **Board Review on Melanoma Therapeutics**, Summer Lecture Series, Division of Hematology & Oncology, Dept. of Medicine, U. of Louisville

Extramural Poster Presentations:

02/08/05 **Nuclear Translocation of 6-Phosphofructo-2-Kinase: Possible Role in Ras Transformation.** Poster Presentation, First Gordon Conferencon Signaling in the Nucleus, **Santa Ynez, CA.**

04/15/05 **Molecular Targeting of 6-Phosphofructo-2-Kinase in Cancer,** Poster Presentation, Annual Conference, The American Society for Clinical Investigation and the Association of American Physicians, **Chicago, IL**.

11/14/05 **Immortalization is Sufficient to Cause the Major Metabolic Alterations of Cancer**, Poster Presentation, American Association for Cancer Research, NCI-EORTC International Conference, **Philadelphia, PA** (Clinical Cancer Research 2005; 11(24), 9142s).

11/14/05 **The Inducible Isozyme of 6-Phosphofructo-2-Kinase is An Essential Downstream Effector of the Oncogene Ras.** Poster Presentation, American Association for Cancer Research, NCI-EORTC International Conference, **Philadelphia, PA** (Clinical Cancer Research 2005; 11(24), 9142s).

09/15/06 **High Expression of 6-Phosphofructo-2-Kinase In Cancer.** Poster Presentation. AACR Molecular Diagnostics in Cancer Therapeutic Development, **Chicago, IL**.

01/25/07 **Subcellular Localization of 6-Phosphofructo-2-Kinase Regulates Glycolytic Flux.** Poster Presentation. AACR/JCA In the Forefront of Basic and Translational Cancer Research, **Waikoloa, HI**.

06/01/08 **A phase II trial of biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, interferon, and digoxin in melanoma patients.** Poster Presentation. American Society of Clinical Oncology Annual Meeting, **Chicago, IL**.

06/01/08 **Transient T Cell Depletion Causes Regression of Melanoma Metastases.** Poster Presentation. American Society of Clinical Oncology Annual Meeting (*selected for Special Discussion Session*), **Chicago, IL**.

03/02/09 **Transient Treg Depletion Causes Regression of Metastases in Stage IV Melanoma Patients.** Poster Presentation. Keystone Conference on Regulatory T cells, **Keystone CO**

06/03/09 **Effect of TKI258 on plasma biomarkers and pharmcokinetics in patients with advanced melanoma.** M. Shi, K. B. Kim, J. Chesney, X. Wang, M. Motwani, J. Wang, M. Steed, O. Anak, G. Jones, J. Saro, J. Kirkwood. J Clin Oncol 27:15s, 2009 (suppl; abstr 9020). Poster Presentation. American Society of Clinical Oncology Annual Meeting, **Chicago, IL**.

06/03/09 **Safety and tolerability of 1-hour intravenous infusion of tremelimumab (CP-675,206) in patients with surgically incurable stage III or IV melanoma.** J. Chesney, A. Ribas, R. Gonzalez, M. Gordon, J. Gomez-Navarro, M. A. Marshall, B. Huang, P. Hsyu, D. Gernhardt. J Clin Oncol 27, 2009 (suppl; abstr e20016) Poster Presentation. American Society of Clinical Oncology Annual Meeting, **Chicago, IL**.

03/15/13 **Stimulation of glucose metabolism by estradiol is mediated by 6-phosphofructo-2-kinase (PFKFB3) (Abstract X4 2011).** Tumor metabolism meeting. Keystone symposia, 2013

06/02/13 **A phase I open-label study of Ad-RTS-hIL-12, an adenoviral vector engineered to express hIL-12 under the control of an oral activator ligand, in subjects with unresectable stage III/IV melanoma.** Gerald P. Linette, Omid Hamid, Eric D. Whitman, John J. Nemunaitis, Jason Chesney, Sanjiv S. Agarwala, Alexander Starodub, John A Barrett, Andrew Marsh, Lori A. Martell, Angela Cho, Thomas D. Reed, Hagop Youssoufian, Andrea Vergara-Silva. J Clin Oncol 31, 2013 (suppl; #3022),

Poster Presentation. American Society of Clinical Oncology Annual Meeting, **Chicago, IL**.

06/02/13 **OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.** Robert Hans Ingemar Andtbacka, Frances A. Collichio, Thomas Amatruda, Neil N. Senzer, Jason Chesney, Keith A. Delman, Lynn E. Spitler, Igor Puzanov, Susan Doleman, Yining Ye, Ari M. Vanderwalde, Robert Coffin, Howard Kaufman. J Clin Oncol 31, 2013 (suppl; #LBA9008), Poster and Oral Presentation (Presenter- H. Kaufman). American Society of Clinical Oncology Annual Meeting, **Chicago, IL**.

06/02/13 **Phase I dose escalation study of recombinant interleukin-21 (rIL-21, BMS-982470) in combination with ipilimumab (Ipi) in patients (pts) with advanced or metastatic melanoma (MM).** Shailender Bhatia, Brendan D. Curti, Michael S. Gordon, Jason Chesney, Theodore Logan, John A. Thompson, Nels Royer, Rachel Bittner, David Fontana, Joseph Grosso, Pamela L. Clemens, Lewis J. Cohen, Christoph Matthias Ahlers, Jon M. Wigginton, Patrick Hwu. J Clin Oncol 31, 2013 (suppl; #TPS3109), Poster and Oral Presentation (Presenter- H. Kaufman). American Society of Clinical Oncology Annual Meeting, **Chicago, IL**.

05/28/14 **Discovery of a PFKFB3 Inhibitor for Phase I Trial Testing that Synergizes with the B-Raf Inhibitor Vemurafenib.** Telang, S., O'Neal, J., Tapolsky, G., Clem B, Kerr, A., Clem, A., Imbert-Fernandez, Y., and Chesney, J.
Metabolism, Diet and Disease BMC Conference, **Washington DC.**

05/28/14 **Simultaneous Inhibition of the Estrogen Receptor and 6-Phosphofructo-2-Kinase (PFKFB3) for the Treatment of ER+ Breast Cancer**
Imbert-Fernandez, Y., Clem, A, O'Neal, J., Telang, S., Clem B, and Chesney, J.
Metabolism, Diet and Disease BMC Conference, **Washington DC.**

06/01/15 **A phase I, dose-escalation, multi-center study of PFK-158 in patients with advanced solid malignancies explores a first-in-man inhbibitor of glycolysis**
Rebecca A. Redman, Paula Raffin Pohlmann, Michael R. Kurman, Gilles Tapolsky, Jason Chesney, American Society for Clinical Oncology Meeting, J Clin Oncol 33, 2015 (suppl; abstr TPS2606)

06/01/15 **Effect of nivolumab (NIVO) in combination with ipilimumab (IPI) versus IPI alone on quality of life (QoL) in patients (pts) with treatment-naïve advanced melanoma (MEL): Results of a phase II study (CheckMate 069).**
Amy Pickar Abernethy, Michael Andrew Postow, Jason Alan Chesney, Kenneth F. Grossmann, Fiona Taylor, Cheryl Coon, Isabelle Gilloteau, Homa Dastani, Paul Gagnier, Caroline Robert, American Society for Clinical Oncology Meeting, J Clin Oncol 33, 2015 (suppl; abstr 9029)

06/02/15 **Tumor size and clinical outcomes in melanoma patients (MEL pts) treated with talimogene laherparepvec (T-VEC)**
Howard Kaufman, Thomas Amatruda, John J. Nemunaitis, Jason Alan Chesney, Keith A. Delman, Lynn E. Spitler, Frances A. Collichio, Merrick I. Ross, Yang Zhang, Mark Shilkrut, Robert Hans Ingemar Andtbacka, American Society for Clinical Oncology Meeting, J Clin Oncol 33, 2015 (suppl; abstr 9074)

06/02/15 **Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.**
F. Stephen Hodi, Michael Andrew Postow, Jason Alan Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann, David F. McDermott, Gerald P. Linette, Nicolas Meyer, Jeffrey K. Giguere, Sanjiv S. Agarwala, Montaser F. Shaheen, Marc S. Ernstoff, David R. Minor, April Salama, Matthew Hiram Taylor, Patrick Alexander Ott, Christine E. Horak, Paul Gagnier, Jedd D. Wolchok. American Society for Clinical Oncology Meeting, J Clin Oncol 33, 2015 (suppl; abstr 9004)

Intramural Poster Presentations (University of Louisville):

09/22/03 **JGBCC, University of Louisville Second Annual Retreat (All Senior/Communicating Author)**

1. Silencing of iPFK-2 Causes a Global Decrease in Nucleic Acid and Protein Synthesis in Cancer Cells
2. Universal Virus Detection

09/23/04 **JGBCC, University of Louisville Third Annual Retreat(All Senior/Communicating Author)**

1. Nuclear Localization of Inducible 6-Phosphofructo-2-Kinase (iPFK-2;PFKFB3)
2. Inducible 6-Phosphofructo-2-Kinase (iPFK-2;PFKFB3) is an Essential Downstream Effector of the Oncogene Ras
3. Ascorbate (Vitamin C): Friend or Foe in the Fight Against Cancer?
4. Genomic Deletion of Inducible 6-Phosphofructo-2-Kinase (PFKFB3) is Lethal
5. Upregulation of Inducible 6-Phosphofructo-2-Kinase (iPFK-2) During T Cell Activation
6. Pharmacophore Targeting of the Fructose-6-Phosphate Binding Site of iPFK-2 Suppresses Tumor Growth

11/09/04 **Research Louisville, University of Louisville (All Senior/Communicating Author)**

1. Pharmacophore Targeting of the Fructose-6-Phosphate Binding Site of iPFK-2 Suppresses Tumor Growth
2. Inducible 6-Phosphofructo-2-Kinase (iPFK-2;PFKFB3) is an Essential Downstream Effector of the Oncogene Ras
3. Nuclear Localization of Inducible 6-Phosphofructo-2-Kinase (iPFK-2; PFKFB3)

09/14/05 **JGBCC, University of Louisville Fourth Annual Retreat (The Olmstead) (All Senior/Communicating Author)**

1. Pharmacologic Inhibition of 6-Phosphofructo-2-Kinase (PFKFB3) Suppresses Cancer Cell Proliferation
2. Radiation Protection with Iron Chelation
3. High Choline Kinase Activity is Essential for Neoplastic Proliferation
4. The Regulatory Subunit Vb of Cytochrome c Oxidase is Required for Malignant Transformation
5. The Inducible Isozyme of 6-Phosphofructo-2-Kinase (PFKFB3) is an Essential Downstream Effector of the Oncogene Ras
6. Immortalization is Sufficient to Cause the Major Metabolic Alterations of Cancer
7. Role of Lactate Dehydrogenase A (LDH-A) in c-Myc Mediated Oncogenic Transformation
8. Nuclear Compartmentalization of a Key Regulator of Glycolysis, 6-Phosphofructo-2-Kinase (PFKFB3)

05/15/06 **JGBCC Molecular Targets Program Annual Retreat (The Brown Hotel) (All Senior/Communicating Author)**

1. Pharmacologic Targeting of 6-Phosphofructo-2-Kinase
2. Ascorbate: Friend or Foe in the Fight Against Cancer
3. The Inducible Isozyme of 6-Phosphofructo-2-Kinase Is an Essential Downstream Effector of the Oncogene Ras

11/29/06 **JGBCC, University of Louisville Fifth Annual Retreat (The Olmstead) (All Senior/Communicating Author)**

1. Denileukin Diftitox Depletes T Regulatory Cells and Causes Regression of Melanoma Metastases in Humans
2. Pharmacological Inhibition of 6-phosphofructo-2-kinase (PFKFB3) Suppresses Tumor Growth
3. Phase II Trial of Biochemotherapy with Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, Interferon and Digoxin in Melanoma Patients

4. The p16INK4a/Rb Family Pathway and Cancer Stem Cell Formation
5. The Requirement of Cytochrome c Oxidase Subunit Vb for Malignant Transformation
6. Requirement of 6-phosphofructo-2-kinase/fructose-2,6- bisphosphatase- 4 (PFKFB4) for Anchorage Independent Growth and Tumorigenesis
7. NADH Mitochondrial Shuttle System is Required for Neoplastic Growth
8. PFKFB3 Interacts with C-RAF

11/28/07 **JGBCC, University of Louisville Sixth Annual Retreat (The Olmstead) (All Senior/Communicating Author Except #7)**

1. Small Molecule Inhibition of 6-Phosphofructo-2-Kinase Activity Suppresses Glycolytic Flux and Tumor Growth
2. The Regulatory Subunit Vb of Cytochrome c Oxidase is Required for Malignant Transformation
3. Transient T Cell Depletion Causes Regression of Melanoma Metastases
4. Requirement of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 (PFKFB4) for Tumorigenesis
5. NADH Shuttle System Is Required For Neoplastic Growth
6. 6-Phosphofructo-2-Kinase (PFKFB3) Traffics to the Nucleus and Stimulates Cell Proliferation
7. A phase II trial of biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, interferon, and digoxin in melanoma patients

10/29/08 **JGBCC, University of Louisville Seventh Annual Retreat (The Olmstead) (All Senior/Communicating Author Except #4)**

1. Inhibition of 6-Phosphofructo-2-Kinase Suppresses Breast Tumor Growth In Vivo
2. Small Molecule Targeting of Choline Kinase Decreases Tumor Growth In Vitro and In Vivo
3. Inhibiting Transaldolase Activity in Cancer Cells
4. The Regulatory Subunit Vb of Cytochrome c Oxidase Is Required for Malignant Transformation
5. Transient T Cell Depletion With DAB/IL2 Causes Regression of Melanoma Metastases: Results of First 37 Patients
6. Requirement of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 (PFKFB4) for Tumorigenesis
7. 6-Phosphofructo-2-Kinase/Fructose-2,6-bisphosphatase-3 (PFKFB3) Localizes to the Nucleus and Enhances Cyclin-Dependent Kinase Activity and the Phosphorylation of the Cell Cycle Inhibitor $p27^{Kip1}$
8. Selective Inhibition of Choline Kinase Interrupts Ras Signaling and Tumor Growth

11/06/09 **JGBCC, University of Louisville Eighth Annual Retreat (The Olmstead) (All Senior/Communicating Author Except #8 and #9)**

1. P27 Is Required for Growth Defects and Apoptosis Caused by PFKFB3 Inhibition
2. Selective Inhibition of Choline Kinase Simultaneously Attenuates MAPK and PI3K/AKT Signaling
3. Identification of Bacterial Species in the Ohio River Using Random Multiplex (RT)-PCR With 3'-Locked Random Primers
4. Small Molecule Targeting of Choline Kinase Decreases Tumor Growth In Vitro and In Vivo
5. Retrospective Analysis of Interleukin-2 (Proleukin) and 5-(3,3-Dimethyle-1-Triazeno) Imidazole-4-Carboxamide (DTIC) as an Alternative Treatment for Resected High-Risk Primary and Regionally Metastatic Melanoma
6. Regulatory subunit Vb of cytochrome c oxidase is required for malignant transformation
7. Association of Clinical Response to Recombinant IL-2/Diptheria Toxin with Increased Survival In Stage IV Melanoma Patients
8. Requirement of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase Isoform 4 (PFKFB4) for Anchorage Independent Growth and Tumorigenesis

9. Retrospective Review of Biochemotherapy-Digoxin for Adjuvant Therapy in Patients at High Risk for Melanoma Recurrence

03/27/10 **Joint UK/UofL Lung Cancer Conference, Lexington, KY**
(All Senior/Communicating Author)

1. Small Molecule Targeting of Choline Kinase Decreases Tumor Growth In Vitro and In Vivo
2. Requirement of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase Isoform 4 (PFKFB4) for Anchorage Independent Growth and Tumorigenesis
3. Small Molecule Inhibition of 6-Phosphofructo-2-Kinase Activity Suppresses Glycolytic Flux and Tumor Growth

11/05/10 **JGBCC, University of Louisville Ninth Annual Retreat (The Olmstead)**
(All Senior/Communicating Author)

1. Clinical Responses to the Regulatory T Cell-Depleting Agent, Denileukin Diftitox, Are Associated With Prolonged Survival in Stage IV Melanoma Patients.
2. Micelle Encapsulation of the Glycolytic Inhibitor 3PO as a Therapeutic Delivery Formulation
3. Small Molecule Targeting of Choline Kinase Decreases Tumor Growth In Vitro and In Vivo.

10/17/11 **Research Louisville!, Louisville**
(All Senior/Communicating Author)

1. Glutathione Synthetase Is Required for the Anchorage Independent Growth of A549 Lung Adenocarcinoma Cells (Presenter: Whitney Goldsberry, M.D, Ph.D. Student)
2. Estradiol stimulates 6-phosphofructo-2-kinase (PFKFB3) expression and glycolysis by breast cancer cells (Presenter: Yoannis Imbert-Fernandez, Ph.D.)
3. Characterization of a novel small moleculeantagonist (PFK-015) of 6-Phosphofructo-2-kinase/ fructose-2,6-bisphosphatase-3 (PFKFB3) that suppresses glucose metabolism and tumor growth (Presenter: Julie O'Neal, Ph.D.)

10/26/12 **JGBCC, University of Louisville 10th Annual Retreat (The Olmstead)**
(All Senior/Communicating Author)

1. Stimulation of Glucose Metabolism by Estradiol Is Mediated by 6-Phosphofructo-2-Kinase (PFKFB3)
2. PFKFB3 Is Required for the Epithelial-Mesenchymal Transition in Tumor Cell Lines
3. Targeting 6-Phoshpofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy Against Cancer

10/25/13 **JGBCC, University of Louisville 11th Annual Retreat (The Olmstead)**

1. Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3) Yoannis Imbert-FernandezRF, Brian Clem, Julie O'Neal, Amy Clem and Jason Chesney
2. Small molecule inhibition of Aspartate Aminotransferase and PFKFB-3 in Pancreatic Cancer Lines Conor O'Neill, Rob Spaulding, Yoannis Imbert-Fernandez, Jason Chesney,
3. 6-Phosphofructo-2-Kinase (PFKFB3) Induces Autophagy as a Survival Mechanism Klarer, Alden C., O'Neal, Julie, Imbert-Fernandez, Y., Clark, Jennifer, Clem, Amy L., Clem, Brian F., Ellis, Steven R., Chesney, Jason, and Telang, Sucheta
4. An anti-glycolytic small molecule inhibitor (PFK158) cooperates with a mutant B-RAF

10/17/14 **JGBCC, University of Louisville 11th Annual Retreat (The Olmstead)**

1. Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3) Yoannis Imbert-FernandezRF, Brian Clem, Julie O'Neal, Amy Clem and Jason Chesney
2. Targeting 6-Phosphofructo-2-kinase/Fructose 2,6-Bisphosphatase (PFKFB4) In Cancer Jason Chesney, Jennifer Clark, John Trent and Sucheta Telang

L. PATENTS

Issued United States Patents:

2001 U.S. Patent #6,255,046
Inducible PFK2 and the Warburg Effect
Inventors: Jason Chesney, Robert Mitchell and Richard Bucala

2002 U.S. Patent #6,413,939
Inducible Phosphofructokinase and the Warburg Effect
Inventors: Jason Chesney, Robert Mitchell and Richard Bucala

2003 U.S. Patent #6,596,851
Inducible PFK2 and the Warburg Effect
Inventors: Jason Chesney, Robert Mitchell and Richard Bucala

2004 U.S. Patent #6,774,227
Therapeutic uses of factors which inhibit or neutralize MIF activity
Inventors: Jason Chesney and Richard Bucala

2012 U.S. Patent #8,088,385
PFKFB3 Inhibitor for the Treatment of Proliferative Cancer
Inventors: Jason Chesney, John Trent, Sucheta Telang, Brian Clem and Jason Meier

2013 U.S. Patent #8,283,332
PFKFB4 Inhibitors and Methods of Using Same
Inventors: Jason Chesney, John Trent and Sucheta Telang

Submitted United States Patents (*currently under review)*:

2009 U. S. Application Number: 61/220,620
Compounds and Methods For Using Compounds That Inhibit Choline Kinase
Inventors: Jason Chesney, John O. Trent, Brian Clem and Sucheta Telang

2011 U. S. Application Number: PCT/US2008/067730
T Cell Depleting Compositions Useful for Treating Cancer
Inventor: Jason Chesney

2012 U.S. Application Number: US2011/025691
Small Molecule Inhibitors of PFKFB3 and Glycolytic Flux and Their Methods of Use as Anti-Cancer Therapeutics
Inventors: Pooran Chand, Jason Chesney, Brian Fl. Clem, Gilles H. Tapolsky, Sucheta Telang and John O. Trent

2015 U.S. Application Number: 62/152,239
Selective PFKFB4 Inhibitors for the Treatment of Cancer
Inventors: John Trent, Jason Chesney and Sucheta Telang.

2015 U.S. Application Number: 62/167,403
Use of PFKFB3 Inhibitors to Activate Tumor Immunity
Inventors: Jason Chesney, Sucheta Telang, and Kavitha Yaddanapudi.

M. RESEARCH FUNDING

Past Support: Basic Research

1. Kentucky Lung Cancer Research Program (Common Wealth of Kentucky)

Title:	**Glycolysis and Lung Cancer**
Role:	*Principal Investigator* (10% effort)
Period of Support:	09/01/03-09/31/06
Total Award:	$225,060
Total Direct Costs:	$204,600

This grant funded a detailed analysis of iPFK-2 protein and mRNA expression in several pathological classifications of primary lung tumors.

2. 1P20 RR18733 Center of Biomedical Research Excellence in Molecular Targets

(Principal Investigator: Donald Miller)

Title:	**Glycolysis and Neoplastic Growth**
Role:	*Project Investigator* (30% effort)
Period of Support:	10/01/03-09/30/06
Total Award:	$11,038,973
Project Total Direct Costs:	$907,015

This grant funded the NMR and XRAY crystallographic determination of the tertiary structure of iPFK-2.

3. Center for Genetics and Molecular Medicine Pilot Project Award

Title:	**Universal Detection of Viruses with Random Multiplex (RT)-PCR**
Role:	*Principal Investigator*
Period of Support:	10/01/05-11/30/06
Total Award:	$15,000
Total Direct Costs:	$15,000

This grant funded an examination of the capacity of random multiplex RT-PCR to detect and identify novel viruses.

4. PCF OGMB04-1166, Department of Defense Predoctoral Traineeship Award

(*Principal Investigator [trainee]: Abdullah Yalcin)*

Title:	**Role of Inducible 6-Phosphofructo-2-Kinase (iPFK-2) in Controlling Metabolic and Growth Activated by Ras in Breast Adenocarcinomas**
Role:	*Mentor/Sponsor* (5% effort)
Period of Support:	02/01/05-01/31/08
Total Award:	$90,000
Total Direct Costs:	$90,000

This grant funded the training of a graduate student, Abdullah Yalcin, to conduct translational research on breast cancer.

5. J.G. Brown Cancer Center P20 Pilot Grant Program

Title: **Targeting T Regulatory Cells in Cancer**
Role: *Principal Investigator*
Period of Support: 03/01/07-02/29/08
Total Award: $46,925
Total Direct Costs $46,925

This grant funded an examination of the effects of T regulatory cell depletion on the progression of metastatic melanoma.

6. J.G. Brown Cancer Center P20 Pilot Grant Program

(Principal Investigator [trainee]: Kristin Nelson, Ph.D.)
Title: **Role of Cytochrome C Oxidase In Tumorigenesis**
Role: *Mentor*
Period of Support: 03/01/07-02/29/08
Total Award: $38,650
Total Direct Costs: $38,650

This grant funded the training of a post-doctoral fellow to examine the requirement of subunit 5b of cytochrome c oxidase in neoplastic transformation.

7. Leukemia and Lymphoma Society Translational Research Grant

Title: **Targeting of Inducible 6-Phosphofructo-2-Kinase in Leukemia**
Role: *Principal Investigator* (25% effort)
Period of Support: 07/01/05-09/01/09
Total Award: $600,000
Total Direct Costs: $540,000

This grant proposed to examine the utility of iPFK2 as a target for the development of compounds that may have selective toxicity to CLL, ALL, AML and CML cells.

8. Department of Defense Breast Cancer Multi-Disciplinary Award

(*Principal Investigator [trainee]: Brian Clem, Ph.D.)*
Title: **Targeting of Inducible 6-Phosphofructo-2-Kinase in Breast Cancer**
Role: *Mentor*
Period of Support: 05/01/05-04/30/09
Total Award: $262,604
Total Direct Costs: $262,604

This grant funded the training of a post-doctoral fellow to identify novel therapeutics for metastatic breast cancer.

9. PM External Research Program

Title: **Control of Metabolic Flux in Lung Cancer**

Role: *Principal Investigator* (5% effort)
Period of Support: 05/01/05-04/30/10
Total Award: $765,032
Total Direct Costs: $520,430

This grant funded an examination of the regulation of metabolic flux in neoplastic bronchial epithelial cells and tissues.

10. 1 R01 CA116428-01

Title: **Targeting of 6-Phosphofructo-2-Kinase in Cancer**
Role: *Principal Investigator* (5% effort)
Period of Support: 10/01/05-07/31/10
Total Award: $1,045,172
Total Direct Costs: $711,000

This grant funded the determination of the mechanism of action of a small molecular inhibitor of iPFK2, termed F6P33.

11. Commonwealth of Kentucky Lung Cancer Research Program Grant

Title: **Targeting Choline Kinase In Lung Cancer**
Role: *Principal Investigator* (10% effort)
Period of Support: 09/01/07-08/31/10
Total Award: $137,486
Total Direct Costs: $124,990

This grant funded a detailed analysis of choline kinase protein and mRNA expression in several pathological classifications of primary lung tumors.

12. University of Louisville Advanced Translational Award

Title: **Pre-Clinical Testing of 3-(3-Pyridinyl)-1-(4-Pyridinyl)-2-Propen-1-One In Autoimmunity**
Role: *Principal Investigator (10%)*
Period of Support: 04/01/10-03/31/11
Total Award: $96,192
Total Direct Costs: $94,306

This grant funded the examination of 3PO for pre-clinical activity against autoimmune diseases in mice.

13. 2R56CA116428-0509 (NIH/NCI)

Title: **Targeting of 6-Phosphofructo-2-Kinase in Cancer**
Role: *Principal Investigator* (20% effort)
Period of Support: 07/01/09-1/31/11
Total Award: $256,921
Total Direct Costs: $173,595

This grant funded the determination of the mechanism of action of a small molecular inhibitor of PFKFB3, termed 3PO. It was a NIH Director's Bridge Award to continue the 1 R01 CA116428-01 research.

14. 3P20RR018733-07S109 Center of Biomedical Research Excellence in Molecular Targets (NCRR)

Title: **Administrative Supplement to Advance Translational Research**
Role: *Co-Investigator* (25%) for Projects 1+3
Period of Support: 10/01/09-09/30/11
Total Award: $759,342
Direct Costs: $398,983 (out of total Direct Costs of $513,069)

This grant funded the examination of novel derivatives of small molecular antagonists of MIF, PFKFB3 and choline kinase.

15. Advanced Cancer Therapeutics Award (Chesney)

Title: **Pre-Clinical Analysis of 3PO and CK37 Derivatives**
Role: *Principal Investigator (1%)*
Period of Support: 09/01/10-03/31/12
Total Award: $175,000
Total Direct Costs: $130,000
This unrestricted sponsored research agreement provides support for the testing of novel synthetic derivatives of 3PO and CK37 for effects on glucose and choline metabolism.

16. Commonwealth of Kentucky Lung Cancer Research Program Grant (Chesney)

Title: **BCC Manhattan Pilot Project for Lung Cancer Screening**
Role: *Principal Investigator (10%)*
Period of Support: 07/01/09-06/30/12
Total Award: $50,000
Total Direct Costs: $50,000

This grant funded the identification of novel PCR-based methods to detect lung cancer in blood.

17. University of Louisville Advanced Translational Award (Chesney)

Title: **Targeting Cancer Metabolism for the Development of Novel Anti-Neoplastic Agents**
Role: *Principal Investigator (10%)*
Period of Support: 07/01/10-06/30/12
Total Award: $174,000
Total Direct Costs: $170,588

This grant funded the identification of novel small molecule antagonists specific for transaldolase, LDH and aspartate aminotransferase.

18. 3P20RR018733-07S109 Center of Biomedical Research Excellence in Molecular Targets (Miller**)**

Title: **Role of the Rb Family of Tumor Suppressors in Glutamine Metabolism**
Role: *Mentor (10%)*
Period of Support 10/01/08-09/31/13
Total Award $11,038,973 (PI: Miller, DM)
Total Direct Costs: $468,619

This grant funded the examination of role of Rb in the regulation of glutamine metabolism in neoplastic cells. I serve as the mentor for Brian Clem, Ph.D.

19. Kentucky Lung Cancer Research Program (Chesney)

Title: **Controlled Inhibition of the Glycolytic Pathway for Lung Cancer-Targeted Therapy**
Role: *Principal Investigator (5%)*
Period of Support: 12/01/10-11/30/13
Total Award: $150,000
Total Direct Costs: $136,364

This grant funded the development of covalently modified 3PO formulations for targeted delivery into acidic neoplastic xenografts in mice.

20. R43 CA165300 01A1 NIH/NCI SBIR (Advanced Cancer Therapeutics)

Title: **PFK-015: An Inhibitor of PFKFB3 to Treat Glioblastomas**
Role: *UofL PI (Sub-Contract; 1.33%)*
Period of Support: 9/17/2012-06/16/2013
Total Award: $57,530
Total Direct Costs: $38,353

This grant funded the testing of a novel PFKFB3 inhibitor for activity against glioblastoma cells and tumors.

21. DOD CDMRP Breast Cancer Post-Doctoral Fellowship (O'Neal)

Title: **Requirement of 6-Phosphofructo-2-Kinase for Transformed Mammary Epithelial Cell Survival and Growth**
Role: *Mentor (5%)*
Period of Support: 4/01/2012-8/30/2014
Total Award: $447,226
Total Direct Costs: $298,816

This grant funded my training of a post-doctoral fellow, Julie O'Neal, to conduct breast cancer research on inhibitors of glycolysis.

Past Support: Clinical Research

Total funds collected from industry sponsors of past trials through 12/31/2012= $511,164.91

1. Novartis Pharmaceuticals Trial Support

Title:	**Open-label Pharmacokinetic Trial of Aldesleukin (Rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma and Metastatic Melanoma With Immunologic Correlative Studies**
Role:	*U. of Louisville Principal Investigator* (<1% effort)
Period of Support:	2005-2008
Total Award:	$75,953.50
Total Direct Costs:	$56,205.59

2. James Graham Brown Cancer Center

Title:	**Phase II Trial To Examine the Efficacy of T Regulatory Cell Depletion Using Diptheria Toxin Conjugate DAB(389)IL2 (ONTAK) For the Treatment of Metastatic Melanoma**
Role:	*Overall Principal Investigator* (<1% effort)
Period of Support:	2006-2009
Total Award:	Intramural
Total Direct Costs:	Intramural

3. Medarex/Bristol-Myers Squibb Trial Support

Title:	**A Randomized, Double Blind Multi-center Phase II Fixed Dose study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV Melanoma**
Role:	*U. of Louisville Principal Investigator* (<1% effort)
Period of Support:	2006-2007
Total Award:	$56,920.00
Total Direct Costs:	$42,120.80

4. Medarex/Bristol-Myers Squibb Trial Support

Title:	**Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group**
Role:	*U. of Louisville Principal Investigator* (<1% effort)
Period of Support:	2007-2009
Total Award:	$12,000.00
Total Direct Costs:	$8,880.00

5. Synta Pharmaceuticals Trial Support

Title:	**Randomized, Double-Blind, Phase III Trial of STA-4783 in Combination with Paclitaxel versus Paclitaxel Alone for Treatment of Chemotherapy-Naïve Subjects With Stage IV Metastatic Melanoma**
Role:	*U. of Louisville Principal Investigator* (<1% effort)

Period of Support: 2007-2009
Total Award: $5,809
Total Direct Costs: $4,299

6. Novartis Pharmaceuticals Trial Support

Title: **A Phase I/II, Open Label, Randomized Three Arm, Dose Escalation Trial to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of RAF265 (CHIR-265) Administered Orally to Patients with Locally Advanced or Metastatic Melanoma**
Role: *U. of Louisville Principal Investigator* (<1% effort)
Period of Support: 2007-2009
Total Award: $171,055.10
Total Direct Costs: $126,580.77

7. Ely Lilly Trial Support

Title: **A Randomized Phase 3 Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-line Treatment of Patients with Metastatic Melanoma**
Role: *U. of Louisville Principal Investigator* (<1% effort)
Period of Support: 2010-2011
Total Award: $8,506.24
Total Direct Costs: $6,294.62

8. Pfizer Trial Support

Title: **A Phase I, Open Label, Single Arm Study to Establish the Safety of Administering CP-675,206 as a One-Hour Infusion in Patients with Surgically Incurable Stage III or Stage IV Melanoma**
Role: *U. of Louisville Principal Investigator* (<1% effort)
Period of Support: 2008-2010
Total Award: $94,818.30
Total Direct Costs: $70,165.54

9. Amgen Trial Support

Title: **A Randomized Trial Of Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy**
Role: *U. of Louisville Principal Investigator* (<1% effort)
Period of Support: 2010-2012
Total Award: $17,105.52
Direct Costs: $12,658.08

10. James Graham Brown Cancer Center

Title: **Phase II Trial of Transient T Cell Depletion With Cyclophosphamide In Stage IV Melanoma**
Role: *Overall Principal Investigator* (<1% effort)
Period of Support: 2009-2012

Total Award (thru 10/12): Intramural
Direct Costs (thru 10/12): Intramural

11. Biogen/Amgen Trial Support

Title: **Study of Safety and Efficacy of OncoVEXGM-CSF With Cisplatin for Treatment of Locally Advanced Head and Neck Cancer**
Role: *U. of Louisville Principal Investigator* (<1% effort)
Period of Support: 2010-2012
Total Award (thru 10/12): $17,729.89
Direct Costs (thru 10/12): $13,120.12

12. James Graham Brown Cancer Center

Title: **A Phase II Open-Label Study of Ipilimumab Administered to Stage IIIC and Stage IV Melanoma Patients after Regulatory T Cell Depletion With Denileukin Diftitox**
Role: *Overall Principal Investigator* (<1% effort)
Period of Support: 2011-2013
Award Costs (thru 10/12): Intramural

13. Eisai Pharmaceuticals Trial Support

Title: **An Open-Label, Multicenter Phase 1b/2 Study of E7080 Alone, and in Combination with Everolimus in Subjects with Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment**
Role: *U. of Louisville Principal Investigator* (<1% effort)
Period of Support: 2012-2013
Award Amount: $8731.12

14. Bristol-Myers Squibb Trial Support

Title: **A Randomized, Open-Label, Multicenter Phase II Study of Ipilimumab Retreatment versus Chemotherapy for Subjects with Metastatic Melanoma who Progressed after Initially Achieving Disease Control with Ipilimumab Therapy**
Role: *U. of Louisville Principal Investigator (<1% effort)*
Period of Support: 2013
Award Amount $6751.72

15. Biogen/Amgen Trial Support

Title: **A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy with or without Panitumumab as First-line Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer, and Cross-over Second-line Panitumumab Monotherapy of Subjects who Fail the Combination Chemotherapy Only Arm**
Role: *U. of Louisville Principal Investigator* (<1% effort)
Period of Support: 2012-2013
Total Award: $35,794.52

Current Support: Basic Research

1. 1R01CA149438 (NCI) (Chesney)

Title:	**Activation of Cyclin-Dependent Kinases by Fructose-2,6-Bisphosphate**
Role:	*Principal Investigator (15%)*
Period of Support:	4/01/11-3/31/16
Total Award:	$1,553,657
Total Direct Costs:	$1,042,722
2014-2015 Direct Costs:	$207,500

This grant funds the characterization of a fructose-2,6-bisphosphate as a novel allosteric regulator of cyclin dependent kinases and cell cycle progression.

2. DOD CDMRP Breast Cancer Post-Doctoral Fellowship (Imbert-Fernandez)

Title:	**Regulation of Glucose Utilization by Estradiol In Breast Cancer**
Role:	*Mentor (5%)*
Period of Support:	7/01/2013-6/30/2016
Total Award:	$447,226
Total Direct Costs:	$298,816
2014-2015 Direct Costs:	$99,605

This grant proposal is to fund my training of a post-doctoral fellow, Yoannis Imbert-Fernandez, to become a breast cancer researcher.

3. P30 Centers of Biomedical Research Excellence Phase III: Transitional Centers Grant (Miller, DM)

Title:	**Molecular Targets Phase III COBRE Animal Model Core**
Role:	*Core Director/Project Leader (10%)*,
Period of Support:	7/01/2013-6/30/2018
Total Award:	$5,608,268 (PI: Miller, DM)
Total Direct Costs:	$3,750,000
Core Award:	$1,177,305 (PI: Chesney, J)
Core Direct Costs:	$784,870
2014-2015 Direct Costs:	$156,974

As the Director of the Animal Model Core, I work with the Co-Director, Dr. Sucheta Telang, to provide transgenic mouse models of tumorigenesis to translational researchers conducting pre-clinical studies of novel diagnostics and therapeutic agents.

4. E0566-2015 Collaborative Matching Grant, School of Medicine, University of Louisville

Title:	**Development of a Choline Kinase Inhibitor**
Role:	PI (5%)
Period of Support:	09/01/2014-06/30/2015
Total Award:	$75,000
Direct Costs:	$75,000

This grant funds the development of a novel small molecule antagonist of choline kinase.

5. NIH (NCI) F30 (PI: Robert Spaulding (MD/PhD student)

Title:	**Integration of Glycolysis with the Epithelial-Mesenchymal Transition**
Role:	Mentor (5%)
Period of Support:	7/01/2014-6/30/2019
Total Award:	$340,731
Direct Costs:	$227,154

This grant proposal funds the training of an MD, PhD student to study the role of PFKFB3 in EMT.

6. NIH (NCI) R21 (PI: Nichola Garbett)

Title:	**Plasma DSC for early detection of disease and therapeutic efficacy in melanoma**
Role:	Co-Investigator (10%)
Period of Support:	10/1/2014-09/30/2016
Total Award:	$422,500
Direct Costs:	$275,000

This application proposes to examine the utility of plasma thermograms for the early detection of melanoma recurrences and for responses to therapy.

7. NIH U01HL127518–01 (PIs: Paula Bates, Eugene Krentsel, Donald Miller)

Title:	**The ExCITE Program: Expediting Commercialization, Innovation, Translation, & Entrepreneurship**
Role:	Co-Investigator (5%)
Period of Support:	3/20/2015-02/28/2018
Total Award:	$3,000,000

This grant provides support for highly innovative technologives to be developed so that commercialization may occur.

Pending Basic Research Support (all in resubmission):

1. NIH (NCI) R01 1R21CA181964-01 (PI: Chesney)

Title:	**Combining 6-Phosphofructo-2-Kinase Inhibitors with Paclitaxel for Lung Cancer**
Role:	PI (10%)
Period of Support:	11/01/2013-10/31/2015
Proposed Total Award:	$412,500
Proposed Direct Costs:	$275,000

NCI Panel ZCA RTRB-Z (M1) Review Completed

Meeting Date:	02/27/2013
Impact Score:	32
Percentile:	**21**

This grant proposal may fund an examination of the synergy between PFKFB3 inhibitors and paclitaxel in NSCLC.

2. NIH (NCI) R01 1R21CA178322-01 (PI: Chesney)

Title:	**Rational Targeting of Estradiol and 6-Phosphofructo-2-Kinase in Breast Cancer**
Role:	PI (10%)
Period of Support:	7/01/2013-6/30/2015
Proposed Total Award:	$412,500
Proposed Direct Costs:	$275,000

NCI Panel ZCA RTRB-Z (M1) Review Completed

Meeting Date:	02/27/2013
Impact Score:	36
Percentile:	**26**

This grant proposal may fund an examination of the synergy between PFKFB3 inhibition and estradiol inhibition against breast cancer cells.

3. NIH (NCI) 1R01CA190854-01 (PI: Chesney)

Title:	**Targeting 6-Phosphofructo-2-Kinase to Suppress BRAFV600E Inhibitor Resistance**
Role:	PI (20%)
Period of Support:	11/01/2014-10/31/2019
Proposed Total Award:	$1,875,000.00
Proposed Direct Costs:	$1,250,000.00

Impact Score:	34
Percentile:	**18**

This grant application is seeking funding for the pre-clinical assessment of the potential of PFKFB3 inhibitors to suppress intrinsic resistance of melanomas to BRAF inhibitors.

Current Support: Clinical Research

Total funds collected from industry sponsors of currently open trials through 04/30/15 = $2,410,547.19

Active (Patients Undergoing Follow-Up Procedures)

1. Biogen/Amgen Trial Support

Title:	**A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment with OncoVEXGM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients with Unresectable Stage IIIb, IIIc and IV Disease**
Role:	*U. of Louisville Principal Investigator* (<1% effort)
Period of Support:	2009-*present*
Award (thru April, 2015):	$437,167.83 (Speedtype #IN090767)

2. Quintiles/Eisai Pharmaceuticals Trial Support

Title:	**A Phase II Open-Label, Multicenter Study of ONTAK in Patients with Stage IIIC and Stage IV Melanoma**
Role:	*Overall Trial Principal Investigator* (<1% effort)
Period of Support:	2010-*present*
Award (thru April, 2015):	$1,082,371.85 (Speedtype #IN091059)

3. Biogen/Amgen Trial Support

Title:	**An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment with OncoVEXGM-CSF for Eligible Melanoma Patients Participating in Study 005/05**
Role:	*U. of Louisville Principal Investigator* (<1% effort)
Period of Support:	2011-*present*
Award (thru April, 2015):	$114,139.20 (Speedtype #IN110405)

4. Bristol-Myers Squibb Trial Support

Title:	**A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination with Ipilimumab in Subjectswith Unresectable Stage III or Stage IV Melanoma**
Role:	*U. of Louisville Principal Investigator (<1% effort)*
Period of Support:	2012-*present*
Award (thru April, 2015):	$169,360.28 (Speedtype #IN120140)

5. Genentech Trial Support

Title:	**A Phase III, Double-Blind, Placebo-Controlled Study of Vemurafenib versus Vemurafenib plus GDC-0973 in Previously Untreated BrafV600-Mutation Positive Patients with Unresectable Locally Advanced or Metastatic Melanoma (Study Number GO28141)**
Role:	*U. of Louisville Principal Investigator (<1% effort)*
Period of Support:	2013-*present*
Award (thru April, 2015):	$48,494.59 (Speedtype #IN130085)

6. Bristol-Myers Squibb Trial Support

Title: **Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination with Ipilimumab vs Ipilimumab alone in Subjects with Previously Untreated, Unresectable or Metastatic Melanoma**
Role: *U. of Louisville Principal Investigator (<1% effort)*
Period of Support: 2013-*present*
Award (thru April, 2015): $232,454.28 (Speedtype #IN140157)

7. Eisai Pharmaceuticals Trial Support

Title: **An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma**
Role: *U. of Louisville Principal Investigator* (<1% effort)
Period of Support: 2010-*present*
Award (thru April, 2015): $44,077.57 (Speedtype #IN101245)

Active (Open for Accrual)

1. Ziopharm Oncology

Title: **A Phase I, Open Label Study of Ad-RTS-hIL-12, an Adenovirus Vector Engineered to Express hIL-12, in Combination With an Oral Activator Ligand, in Subjects With Unresectable Stage III or IV Melanoma**
Role: *U. of Louisville Principal Investigator* (<1% effort)
Period of Support: 2011-*present*
Award (thru April, 2015): $ 31,179.15 (Speedtype #IN111169)

2. James Graham Brown Cancer Center

Title: **A Phase I/II Trial of Vemurafenib and Metformin Administered to Unresectable Stage IIIC and Stage IV BRAFV600E+ Melanoma Patients**
Role: *Overall Principal Investigator* (<1% effort)
Period of Support: 2012-*present*
Award Amount: Intramural

3. James Graham Brown Cancer Center

Title: **A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients**
Role: *Overall Principal Investigator* (<1% effort)
Period of Support: 2011-*present*
Award Amount: Intramural

4. Amgen

Title: **A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Previously Untreated, Unresectable, Stage IIIb-IV Melanoma**
Role: *U. of Louisville Principal Investigator (<1% effort)*
Period of Support: 2013-*present*

Award (thru April, 2015): $118,068.24 (Speedtype #121250)

5. Genentech Trial Support

Title: **A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients with Surgically Resected, Cutaneous BRAF-Mutant Melanoma at High Risk for Recurrence**
Role: *U. of Louisville Principal Investigator (<1% effort)*
Period of Support: 2013-*present*
Award (thru April, 2015): $16,107.40 (Speedtype #IN121306)

6. Angimmune Trial Support

Title: **Phase I/II Trial of the A-dmDT390-bisFv (UCHT1) Fusion Protein in Combination with Ionizing Radiation for the Treatment of Stage IV Melanoma**
Role: *U. of Louisville Principal Investigator (<1% effort)*
Period of Support: 2013-*present*
Award (thru April, 2015): $37,901.64 (Speedtype #IN140094)

7. Merck Trial Support

Title: **Expanded Access of MK-3475 (Pembrolizunab) in Metastatic Melanoma Patients with Limited to No Treatment Options**
Role: *U. of Louisville Principal Investigator (<1% effort)*
Period of Support: 2014-*present*
Award Amount: *Pro Bono*

8. Amgen Trial Support

Title: **A Phase 2, Multicenter, Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec in Subjects With Unresected, Stage IIIb to IVM1a Melanoma**
Role: *U. of Louisville Principal Investigator (<1% effort)*
Period of Support: 2014-*present*
Award (thru April, 2015): $12,378.92 (Speedtype #IN131354)

9. James Graham Brown Cancer Center

Title: **A Phase I/II Trial of Dabrafenib, Trametinib and Metformin Administered to Unresectable Stage IIIC and Stage IV BRAF V600E + Melanoma Patients**
Role: *Overall Principal Investigator* (<1% effort)
Period of Support: 2014-*present*
Award Amount: Intramural

10. Bristol-Myers Squibb Trial Support

Title: **A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen**
Role: *U. of Louisville Principal Investigator (<1% effort)*

Period of Support: 2014-*present*
Award (thru April, 2015): $66,846.24 (Speedtype #IN150127)

11. National Cancer Institute (SWOG)

Title: **Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer**
Role: *U. of Louisville Principal Investigator (<1% effort)*
Period of Support: 2014-*present*
Award Amount Pending Accrual

12. Neostem

Title: **Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In GM-CSF vs. PBMCs In GM-CSF for The Treatment Of Metastatic Melanoma**
Role: *U. of Louisville Principal Investigator (<1% effort)*
Period of Support: 2015-*present*
Award Amount Pending Accrual

Pending Final IRB Approval

1. National Cancer Insitute (ECOG-ACRIN)

Title: **A Randomized Phase II Trial of Ipilimumab with or Without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma**
Role: *U. of Louisville Principal Investigator (<1% effort)*
Period of Support: 2015-*present*
Award Amount Pending Accrual

2. National Cancer Institute (SWOG)

Title: **A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma**
Role: *U. of Louisville Principal Investigator (<1% effort)*
Period of Support: 2015-*present*
Award Amount Pending Accrual

3. National Cancer Institute

Title: **Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Melanoma That Cannot Be Removed by Surgery**
Role: *U. of Louisville Principal Investigator (<1% effort)*
Period of Support: 2015-*present*
Award Amount Pending Accrual

4. Amgen

Title: **A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects in Europe With Unresected Stage IIIB to IVM1c Melanoma**
Role: *U. of Louisville Principal Investigator (<1% effort)*

Period of Support: 2015-*present*
Award Amount Pending Accrual

5. Amgen

Title: **A Phase 1, Multicenter, Open-Label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors**
Role: *U. of Louisville Principal Investigator (<1% effort)*
Period of Support: 2015-*present*
Award Amount Pending Accrual

6. Medimmune

Title: **A Phase 1b/3 Open-Label Study to Evaluate the Safety and Tolerability of MEDI0680 (anti-PD1) in Combination with MEDI4736 (anti-PD-L1) in Subjects with Advanced Malignancies**
Role: *U. of Louisville Principal Investigator (<1% effort)*
Period of Support: 2015-*present*
Award Amount Pending Accrual

N. CLINICAL SERVICE

2005-*present* **Multi-Disciplinary Outpatient Hematology/Oncology Clinic**

Clinical Service: One full-day clinic per week (average=25 hematology and oncology outpatients/week)

Site: 3rd Floor Multi-Disciplinary Clinic, James Graham Brown Cancer Center

2005-*present* **Hematology/Oncology Inpatient Service**

Clinical Service: 2 months per year (average=20 inpatients/day; Current academic year: December 2014, March 2015)

Sites: U. of Louisville Hospital, Norton Downtown Hospital, Jewish Downtown Hospital and the Louisville VA Hospital

2005-*present* **Clinical Trial Principal Investigator**

Clinical Service: PI on an annual average of 12 open clinical trials in melanoma, renal cell carcinoma, head/neck and lung cancers

Sites: U. of Louisville Hospital, Norton Downtown Hospital, Jewish Downtown Hospital and the Louisville VA Hospital

2006-*present* **Clinical Trial Data and Safety Monitoring** (as Chairman of the DSMC)

Clinical Service: Real-time cancer therapeutic clinical trial monitoring (serious adverse events); Chair of James Graham Brown Cancer Center Data and Safety Monitoring Committee (quarterly data and safety reviews of all therapeutic cancer trials)

Sites: U. of Louisville Hospital, Norton Downtown Hospital, Jewish Downtown Hospital and the Louisville VA Hospital

2006-*present* **Director, Clinical Research Program of the James Graham Brown Cancer Center**

Clinical Service: Supervision of 25 staff in the James Graham Brown Cancer Center Clinical Trials Office, including the Director of Clinical Operations, Director of Regulatory Affairs, 6 Regulatory Assistants, 5 Research Nurses, 6 Clinical Trial Coordinators, 2 Financial Coordinators, 3 Tissue Repository Laboratory Technicians and an Administrative Assistant; Oversight of the management and conduct of 150 therapeutic trials including sponsored, cooperative group and investigator-initiated trials; Liaison with cancer trial principal investigators, regulatory bodies and hospitals; Serve as Director of the James Graham Brown Cancer Center Tissue Repository

Sites: U. of Louisville Hospital, Norton Downtown Hospital, Jewish Downtown Hospital and the Louisville VA Hospital

O. PUBLICATIONS (communicating author [#])

1. **Chesney, J.,** Mahoney, J.R., and Eaton, J.W. A spectrophotometric assay for chlorine containing compounds. *Anal. Biochem.* 196:262-266, 1991. PMID: 1663708

2. Bucala, R., Spiegel, L.A., **Chesney, J.**, Hogan, M., and Cerami, A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. *Mol. Medicine* 1:71-81, 1994. PMID: 8790603

3. **Chesney, J.,** Kondoh, T., Conrad, J.A., and Low, W.C. Collagenase-induced intrastriatal hemorrhage in rats results in long-term locomotor deficits. *Stroke* 26(2):312-317, 1995. PMID: 7831705

4. Bianchi, M., Bloom, O., Raabe, T., Cohen, P.S., **Chesney, J.**, Sherry, B.,Schmidtmayerova, H., Calandra, T., Zhang, X., Bukrinsky, M., Ulrich, P., Cerami, A., and Tracey, K.J. Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. *J. Exp. Med.* 183:927-936, 1996. PMID: 8642296

5. **Chesney, J.,** Eaton, J.W., and Mahoney, J.R. Bacterial glutathione: a sacrificial defense against chlorine compounds. *J. Bacteriology* 178:2131-2135, 1996. PMID: 8606194

6. Bacher, M., Metz, C., Calandra, T., Mayer, K., **Chesney, J.**, Lohoff, M., Gemsa, D., Donnelly, T., and Bucala, R. An essential regulatory role for MIF in T cell activation. *Proc. Natl. Acad. Sci. USA* 93:7849-7854, 1996. PMID: 8755565

7. Bacher, M., Meinhardt, A., Lan, H.Y., Mu, W., **Chesney, J.,** Metz, C.N., Gemsa, D., Donnelly, T., Atkins, R.C., and Bucala, R. MIF expression in experimentally-induced endotoxemia. *Am. J. Pathol.* 150:235-246, 1997. PMID: 9006339

8. **Chesney, J.,** Bacher, M., Bender, A., and Bucala, R. The peripheral blood fibrocyte is a potent antigen presenting cell capable of priming naive T cells *in situ*. *Proc. Natl. Acad. Sci. USA* 94:6307-6312, 1997. PMID: 9177213

9. **Chesney, J.** and Bucala, R. Peripheral blood fibrocytes: novel fibroblast-like cells that present antigen and mediate tissue repair. *Biochem. Soc. Trans.* 25:520-523, 1997. PMID: 9191147

10. **Chesney, J.,** Metz, C., Stavitsky, A., Bacher, M., and Bucala, R. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. *J. Immunol.* 160:419-425, 1998. PMID: 9551999

11. Bacher, M., Meinhardt, A., Lan, H. Y., Dhabar, F., Wu, M., Metz, C. N., **Chesney, J.,** Gemsa, D., Donnelly, T., Atkins, R. C., and Bucala R. MIF expression in the rat brain: implications for neuronal function. *Mol. Medicine* 4(4): 217-230, 1998. PMID: 9606175

12. Grab, D. J., Lanners, H., Martin, L. N., **Chesney, J**., Cai, C., Adkisson, H. D., and Bucala, R. Interaction of Borrelia burgdorferi with peripheral blood fibrocytes, antigen presenting cells with the potential for connective tissue targeting. *Mol Medicine* 5(1):46-54, 1999. PMID: 9606175

13. **Chesney, J.,** Mitchell, R., Benigni, F., Bacher, M., Spiegel, L., Al-Abed, Y., Han, J. H., Metz, C., and Bucala, R. An inducible gene for 6-phosphofructo-2-kinase (iPFK-2) with an AU-rich mRNA instability element: Role in tumor cell glycolysis and the Warburg Effect. *Proc. Natl. Acad. Sci. USA* 96(6):3047-3052, 1999. PMID: 10077634

14. **Chesney, J.,** Metz, C., Bacher, M., Peng, T., Meinhardt, A., and Bucala, R.. An essential role for

macrophage migration inhibitory factor in angiogenesis and the growth of a murine lymphoma. *Mol. Medicine* 5(3):181-191, 1999. PMID: 10404515

15. **Chesney, J.** and Bucala, R. Peripheral blood fibrocytes: Mesenchymal precursor cells and the pathogenesis of fibrosis. *Current Rheumatology Reports*, 2(6):501-505, 2000. PMID: 11123104

16. **Chesney, J.** and Bucala, R. Peripheral blood fibrocytes: in vitro culture techniques. *Human Cell Culture Series: Primary Mesenchymal Cells.* Kluwer Academic Publishers, The Netherlands, 5:78-84, 2000.

17. **Chesney, J.** and Bucala, R. Inducible 6-phosphofructo-2-kinase (iPFK-2): Role in the Warburg effect and tumor hypoxia. *Biotechnology International*, 3:1-7, 2001

18. Mitchell, R, Liao H., **Chesney, J.**, and Bucala, R. Macrophage migration inhibitory factor sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response. *Proc. Natl. Acad. Sci. USA* 99(1):345-350, 2002. PMID: 11756671

19. Senter, P.D., Al-Abed, Y., Metz, C.N., Benigni, F., Mitchell, R.A., **Chesney, J.**, Han, J., Nelson, S. D., Todaro G.J., and Bucala R. Irreversible inhibition of macrophage migration inhibitory factor tautomerase and biological activities by acetominophen metabolites. *Proc. Natl. Acad. Sci. USA* 99(1):144-149, 2002. PMID: 11773615

20. Atsumi, T.*****, **Chesney, J.***, Metz, C., Leng, L., Donnelly, S., Makita, Z., Mitchell, R. and Bucala, R. High expression of inducible 6-phosphofructo-2-kinase (iPFK-2; PFKFB3) in human cancers. *Cancer Research* 62 (20):5881-5887, 2002. (*authors contributed equally) PMID: 12384552

21. Grab, D. J., Salem, M. L., **Chesney, J.,** Bucala R., and Lanners, N. H. A Role for Peripheral Blood Fibrocytes in Lyme Disease. *Medical Hypothesis,* 59(1):1, 2002. PMID: 12160674

22. Mahlknecht U, **Chesney J**, Hoelzer D and Bucala R. Cloning and chromosomal characterization of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 gene (PFKFB3, iPFK2). *Int J Oncol.* 2003 Oct;23(4):883-91. PMID: 12963966

23. **Chesney, J. [#],** Telang S., Yalcin, T., Clem, A., Wallis, N. and Bucala R. Targeted disruption of inducible 6-phosphofructo-2-kinase results in embryonic lethality. *Biochemical and Biophysical Research Communications*. 331(1):139-46, 2005. PMID: 15845370

24. Telang S., Yalcin A., Clem A. L., Bucala R., Lane A. N., Eaton J. W.,**Chesney J.[#]** Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. *Oncogene*, 25(55): 7225-34, 2006. PMID: 16715124

25. **Chesney J.[#]** 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis. *Clinical Nutrition and Metabolic Care*. 9(51): 535-539. 2006. PMID: 16912547

26. **Chesney J.[#]** Fibrocytes: Immunologic features. In: Fibrocytes: New Insights Into Tissue Repair and Systemic Fibroses, World Scientific Publishing, Singapore (ed Bucala, 268 pp), 19-36, 2007.

27. Telang, S., Clem, A.L., Eaton, J.W., and **Chesney J.[#]** Depletion of ascorbic acid restricts angiogenesis and retards tumor growth in a mouse model. *Neoplasia*, 9(1): 47-56, 2007. PMID: 17325743

28. Clem, A., Sims, J., Eaton, J.W., Telang, S., and **Chesney J.[#]** Virus detection and identification using random multiplex (RT)-PCR with 3'-locked random primers. *Virology Journal*, 4(1):65, 2007. PMID: 17598900

29. Telang, S., Nelson, K., Lane, A., and **Chesney J.**[#] The oncoprotein H-Ras^{V12} increases mitochondrial metabolism. *Molecular Cancer*, 6(1):77-83, 2007. PMID: 17598900

30. Clem, B., Telang, S., Clem, A., Yalcin, A., Meier, J., Simmons, A., Rasku, M., Dean, W., Trent, J.O., and **Chesney J.**[#] Small molecule inhibition of 6-phosphofructo-2-kinase activity suppresses established tumor growth. *Molecular Cancer Therapeutics*, 7(1):110-20, 2008. PMID: 18202014

31. Liu, Y., El-Naggar, S., Clem B., **Chesney. J.**, Dean, D.C. The Rb/E2F pathway and Ras activation regulate RecQ helicase gene expression. *Biochemical Journal*, 412(2):299-306, 2008. PMID: 18215118

32. Rasku, M., Clem, A.L., Telang, S., Taft, B., Gettings, K., Gragg, H., Cramer, D., Lear, S. C., McMasters, K.M., Miller, D. M., and **Chesney J.**[#] Transient T cell depletion causes regression of melanoma metastases. *Journal of Translational Medicine*, 6(1):12, 2008. PMID: 18334033

33. Thornburg, J., Nelson, K., Clem, B. F., Lane, A., Arumugam, S., Simmons, A., Eaton, J. W., Telang, S. and **Chesney J.**[#] Targeting aspartate aminotransferase in breast cancer. *Breast Cancer Research*, 10:R84, 2008. PMID: 18922152

34. Gajewski, T.F., **Chesney, J.,** Curriel T.J. Emerging strategies in regulatory T-cell immunotherapies. *Clin Adv Hematol Oncol*, 7(1):1-10, 2009. PMID: 19288606

35. Liu Y., Clem, B. F., Zuba-Surma, E., El-Naggar, S., Telang, S., Jenson, A.B., Ratajczak, M., **Chesney, J**., and Dean, D. C. A novel tumor suppressor function for the cell contact inhibition signaling pathway: Blocking reprogramming of differentiated somatic cells to cancer stem cells. *Cell (Stem Cell)*, 4(4):336-47, 2009. PMID: 19341623

36. Rasku, M. A. and **Chesney J.**[#] Medical management of melanoma. *Louisville Medicine,* 57(5): 13-18, 2009.

37. Jaglal MV, Laber DA, Arnold FW, Miller DM, **Chesney J**, Kloecker GH. Obtaining routine blood cultures during interleukin-2-containing therapy Is unnecessary. *Am J Clin Oncol*. 2009 Aug;32(4):429-31, 2009. PMID: 19451801

38. Yalcin, A, Clem, BF, Simmons, A, Lane, A, Nelson, K, Clem, A, Brock, E, Siow, D, Wattenburg, B, Telang, S, and **Chesney J.**[#] Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases. *J Biol Chem,* 284(36): 24223-32, 2009. PMID: 19473963

39. Yalcin, A., Telang, S., Clem, B. and **Chesney J.**[#] Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. *Experimental and Molecular Pathology*, 86(3), 174-179, 2009. PMID: 19454274

40. Khan, M.I., Laber, D., **Chesney, J.,** and Miller, D.M. Digitalis, a targeted therapy for cancer? *The American Journal of the Medical Sciences*. 337(5):355-9, 2009. PMID: 19440057

41. Huo Y, Guo X, Li H, Wang H, Zhang W, Wang Y, Zhou H, Gao Z, Telang S, **Chesney J**, Chen YE, Ye J, Chapkin RS, Wu C. Disruption of inducible 6-phosphofructo-2-kinase ameliorates diet-induced adiposity but exacerbates systemic insulin resistance and adipose tissue inflammatory response. *J Biol Chem* 285(6):3713-21, 2010. PMID: 19948719

42. Yalcin, A, Clem, BF, Makoni, S, Clem, A, Nelson, K, Thornburg, J, Siow, D, Lane, AN, Brock, SE, Goswami, U, Eaton, JW, Telang, S, and **Chesney J.**[#] Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling. *Oncogene* 29(1):139-49, 2010. PMID: 19855431

43. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr, Grob JJ, **Chesney J**, Chin K, Chen K, Hoos A, O'Day SJ, Lebbé C. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. *Lancet Oncology* 11(2):155-164. 2010. PMID: 20004617

44. Clem, B., Clem, A., Yalcin, A., Goswami, U., Arumugam, S., Telang, S., Trent, J., and **Chesney J.**[#] A novel small molecule antagonist of choline kinase-α that simultaneously suppresses MAPK and PI3K/AKT signaling. *Oncogene*, 30(30):3370-80, 2011. PMID: 21423211

45. Natarajan, N, Telang, S., and **Chesney J.**[#] Novel immunotherapeutic agents and small molecule antagonists of signaling kinases for the treatment of metastatic melanoma. *Drugs*, 71(10):1233-50, 2011. PMID: 21770473

46. **Chesney J.**[#] and Kelly M. McMasters. Tumor infiltrating lymphocytes - ready for prime time in melanoma? *Nature Clinical Oncology*, 8(8):449-50*,* 2011. PMID: 21727931

47. Kim, K., **Chesney, J.,** Robinson, D., Gardner, H., Shi, M., and Kirkwood, J. M. Effect of dovitinib (TKI258), an inhibitor of FGFR, VEGFR, and PDGFR on plasma biomarkers in patients with advanced melanoma. *Clinical Cancer Research,* 17(23):7451-61, 2011. PMID: 21976540

48. Akter S., Clem, B. F., Lee, H. J., **Chesney, J.,** and Bae Y. Block copolymer micelles for controlled delivery of glycolytic enzyme inhibitors. *Pharmaceutical Research*, Oct 28. [Epub ahead of print] 2011. PMID: 22033882

49. Telang, S. Rasku, M. A., Clem, A. L., Carter, K., Klarer, A. C., Badger, W. R., Milam, R. A., Rai, S. N., Pan, J., Gragg, H., Clem, B. F., McMasters, K. M., Miller, D. M. and **Chesney J.**[#] Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage iv melanoma*. BMC Cancer*, 11(1):515-523, 2011**.** PMID: 22165955

50. **Chesney J.**[#] and Telang, S[#]**.** Regulation of glycolytic and mitocondrial metabolism by Ras. Special Issue on Bioenergetics of Cancer, *Current Pharmaceutical Biotechnology*, Jun 1. [Epub ahead of print] 2012. PMID: 22201601 ([#]dual communicating)

51. Telang, S.[#], Clem, B. F., Klarer, A. C., Clem, A. L., Trent, J. O., Bucala, R. and **Chesney, J.**[#] Small molecule inhibition of 6-phosphofructo-2-kinase suppresses T cell activation. *Journal of Translational Medicine,* 10(1):95, 2012. PMID: 22591674 ([#]dual communicating)

52. Telang, S., Nelson, K. K., Siow, D.L., Yalcin, A., Thornburg, J. M., Imbert-Fernandez, Y., Klarer, A. C., Farghaly, H., Clem, B. F., Eaton, J. W., and **Chesney J.**[#] Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth. *Molecular Cancer*, 11(1):60-72, 2012. PMID: 22917272

53. Clem, B. and **Chesney, J.**[#] Regulation of metabolism by Rb. *Clinical Cancer Research*, 18(22):6096-6100, 2012. PMID: 23154086

54. Ribas, A., **Chesney, J.**, Gordon, M.S., Aberneth, A. P., Logan, T. F., Lawson, D. H., Chmielowksi, B., Huang, B., Wang, E., Poe-Hirr, H., Gomez-Navarro, J., Gerhardt, D., Marshall, M. A., and Gonzalez, R. C. Safety profile and pharmacokinetic analysis of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. *Journal of Translational Medicine*, 10(1):236, 2012. PMID: 23171508

55. Liu Y, Sanchez-Tillo E, Lu X, Huang L, Clem B, Telang S, Jenson AB, Cuatrecasas M, **Chesney J**, Postigo A, Dean DC. Sequential Inductions of the ZEB1 Transcription Factor Caused by

Mutation of Rb and then Ras are required for Tumor Initiation and Progression. *J Biol Chem*. 288(16):11572-80, 2013. PMID:23443660

56. Redman, R. A. and **Chesney J.**[#] Collision between an Indolent B-cell Lymphoma and a Microsatellite Unstable Adenocarcinoma of the Colon. *Journal of Hematology & Thromboembolic Diseases*, 1: 110-113, 2013.

57. Clem, B.F., O'Neal, J., Tapolsky, G., Clem, A., Imbert-Fernandez, Y., Klarer, A. C, Redman, R., Trent, J.O., Telang, S. and **Chesney, J.**[#] Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. *Molecular Cancer Therapeutics (AACR)* 12(8), 1-10, 2013. PMID: 23674815 **Article selected for cover page of August 2013 Molecular Cancer Therapeutics Issue.**

58. O'Neal and **Chesney, J.**[#] Targeting metabolic enzymes in cancer – Clinical trials update. *Current Enzyme Inhibition* 12(8):1-10, 2013.

59. De Bock, K., Georgiadou, M., Schoors, S., Cauwenberghs, S., Cascante, M., Telang, S., De Berardinis, R., Schoonjans, L., Vinckier, S., **Chesney, J.**, Ghesquière, B., Gerhardt, H., Dewerchin, M. & Carmeliet, P. Role of PFKFB3-Driven Glycolysis in Vessel Sprouting. *Cell*, 154: 651–663, 2013. PMID: 23911327

60. Liu Y, Sánchez-Tilló E, Lu X, Clem B, Telang S, Jenson AB, Cuatrecasas M, **Chesney J**, Postigo A, Dean DC. Rb1 Family Mutation Is Sufficient for Sarcoma Initiation. *Nature Communications*, 4:2650, 2013. PMID: 24150016

61. Schoors S, De Bock K, Cantelmo AR, Georgiadou M, Ghesquière B, Cauwenberghs S, Kuchnio A, Wong BW, Quaegebeur A, Goveia J, Bifari F, Wang X, Blanco R, Tembuyser B, Cornelissen I, Bouché A, Vinckier S, Diaz-Moralli S, Gerhardt H, Telang S, Cascante M**, Chesney J**, Dewerchin M, Carmeliet P. Partial and Transient Reduction of Glycolysis by PFKFB3 Blockade Reduces Pathological Angiogenesis. *Cell Metabolism*, 19(1):37-48, 2014. PMID: 24332967

62. Liu Y, Sanchez-Tillo E, Lu X, Huang L, Clem B, Telang S, Jenson AB, Cuatrecasas M, **Chesney J**, Postigo A, Dean DC. The ZEB1 Transcription Factor Acts in a Negative Feedback Loop with miR200 Downstream of Ras and Rb1 to Regulate Bmi1 Expression. *J Biol Chem*. 2013 Dec 26 (Epub ahead of print). PMID: 24371144

63. Klarer, A., O'Neal, J., Ellis, S., Clem, A.L., **Chesney J.**[#] and Telang S. 6-Phosphofructo-2-Kinase Inhibition Induces Autophagy as a Survival Mechanism. *Cancer and Metabolism*, 2(1):2 2014. PMID: 24451478

64. Imbert-Fernandez Y., Spaulding R., Lanceta L., Clem B.F., O'Neal J., Clem A., Telang S. and **Chesney J**[#]. Estradiol Stimulates Glucose Metabolism via 6-Phosphofructo-2-Kinase (PFKFB3). *J Biol Chem*, 289(13):9440-8, 2014. PMID: 24515104

65. Yalcin, A., Telang, S., Clem, A., O'Neal, J., Imbert-Fernandez, Y., Klarer, A., Clem, B. F., and **Chesney, J.**[#] 6-Phosphofructo-2-Kinase (PFKFB3) Promotes Cell Cycle Progression and Suppresses Apoptosis via Cdk1-Mediated Phosphorylation of p27. *Cell Death and Disease (Nature)*, 5, e1337, 2014. PMID: 25032860

66. **Chesney J.,** Clark J., Klarer A., Imbert-Fernandez, Y., Lane A.N. and Telang S. Fructose-2,6-Bisphosphate Synthesis by 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase 4 (PFKFB4) Is Required for the Glycolytic Response to Hypoxia and Tumor Growth. *Oncotarget* 5(16):6670-86, 2014 PMID: 25115398

67. Stathem M., Marimuthu S., O'Neal J., Rathmell, J., **Chesney, J.,** Beverly L., Siskind L. Glucose availability and glycolytic metabolism dictate glycosphingolipid levels. *Journal of Cellular Biochemistry*, 2014 Aug 21. [Epub ahead of print] PMID: 25145677

68. Liu, Y., Lu, X., Huang, L., Wang, W., Jiang, G., Dean, K., Clem B., Telang, S., Jenson, A.B., Cuatrecasas, M., **Chesney, J.,** Darling, D., Postigo, A., and Dean, D. Different Thresholds of ZEB1 are Required for Ras-Mediated Tumor Initiation and Metastasis. *Nature Communications,* 2014 Dec 1;5:5660 [Epub ahead of print] PMID: 25434817

69. Andtbacka, RH, Kaufman, HL, Collichio, F, Amatruda, T, Senzer, N., **Chesney**, **J**, Delman, K., Spitler, L.E., Puzanov, I., Agarwala, S.S., Milhem, M., Cranmer, L., Curti, B., Lewis, K., Ross, M., Guthrie, T., Linette, G., Daniels, G., Harrington, K., Middleton, M. R., Miller, W. H., Ye, Y., Yao, B., Doleman, S., VanderWalde, A., Gansert, J. and Coffin, R. Improved Durable Response Rate With Talimogene Laherparepvec in Unresected Stage IIIB/IIIC/IV Melanoma. *Journal of Clinical Oncology*, 2015 May 26 [Epub ahead of print] PMID: 26014293

70. Postow, M.A., **Chesney, J.,** Pavlick, A.C., Rober, C., Grossmann, K., McDermott, D., Linette, G., Meyer, N., Giguere, J. K., Agarwala, S., Shaheen, M., Ernstoff, M.S., Minor, D., Salama, A.K., Taylor, M., Ott, P.A., Rollin, L.M., Horak, C., Gagnier, P., Wolchok, J., Hodi, F. S. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. *New England Journal of Medicine*, 372(21):2006—2017, 2015. PMID: 25891304

71. **Chesney, J.,** Clark, J., Lilibeth, L., Trent, J. O., Telang, S., Targeting the Sugar Metabolism of Tumors with a First-In-Class 6-Phosphofructo-2-Kinase (PFKFB4) Inhibitor. *Oncotarget,* 6(20): 18001-18011, 2015. PMID: 26221874

72. **Chesney J.** and Mitchell, R. A.. 25 Years On – A Retrospective on MIF in Tumor Angiogenesis. In press, *Molecular Medicine*, 2015.